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1. Deep vein thrombosis and the post-thrombotic 
syndrome
Venous throm bo-em bolism  (VTE) usually manifests itself w ith thrombus  
located in the veins of extrem ities (deep vein thrombosis (DVT)) and/or the 
pulmonary arteries (pulmonary embolism (PE)). Because of the sim ilarities in 
diagnosis, treatment and prognosis and the overlap in pathophysio logy DVT 
and PE are now considered a single clinical entity1.
VTE is common with an estimated incidence rate exceeding 1 per 1000 persons 
in the general population12. Risk factors for VTE include inherited thrombophilia  
(for example protein C, S and antithrombin deficiency, mutation of Factor V 
Leiden or prothrombin) and several types of acquired risk factors like increasing 
age, prolonged immobility, malignancy, major surgery, multiple trauma, 
pregnancy, obesity, hormone replacement therapy or oral contraceptives3. 
The treatment comprises of anticoagulation treatment in order to prevent 
further extension of the thrombus and pulmonary embolism, and compression  
therapy with elastic stockings to prevent the post-thrombotic syndrome (PTS).
Despite appropriate anticoagulant therapy, at least one of every 2-3 patients 
with DVT will develop post-thrombotic sequelae4. The reported incidence of 
PTS shows considerable variability, due to large differences among studies in 
terms of study design, definition of PTS, sample size, length of follow-up, and 
use of elastic compression stockings. PTS remains a significant cause of 
chronic illness, with considerable socio-econom ic consequences for both 
patient and health care services. In a Swedish study the costs of treating post- 
th rom botic complications was about 75% of the costs of primary DVT5. In 1995 
treatment of chronic venous insufficiency (CVI) in France and Belgium consumed 
about 2.5% of the total health care budget6. An US study estimated that the 
annual direct costs of PTS was at least $200 m illion7.
C lin ica l s ca le s  o f PTS
The complaints of patients with PTS include pain, heaviness, swelling, cramps 
and itching. Symptoms of PTS are venous dilatation, varicosities, skin 
pigmentation, eczema, lipodermatosclerosis (chronic inflammation and 
fibrosis of the skin and subcutaneous tissues of the medial lower limb) and 
atrophie blanche. Ulceration, often precipitated by minor trauma, arises in a 
considerable number of patients and is characteristically chronic and indolent 
with a high recurrence rate, once healing has occurred.
11
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There is no gold standard test for the diagnosis PTS. The diagnosis PTS is 
based on the above mentioned clinical manifestations in patients with a history  
of DVT, irrespective of the presence of venous abnormalities as shown by 
invasive or non-invasive diagnostic procedures. In the absence of characteristic  
signs and symptoms, the demonstration of venous abnormalities (such as 
reflux, persistent venous obstruction or both) does not, in itself, allow a patient 
with a history of DVT to be defined as having PTS. As it usually takes 3 to 6 
months after acute DVT for the initial pain and swelling to resolve, a diagnosis  
of PTS should be deferred until after half a year.
12
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There is a large variation among published studies as to its clinical classification. 
Several clin ical scales for the diagnosis of PTS are available. Two diagnostic  
scales, the CEAP classification and the V illa lta scale, have been used mostly; 
both are presented in table 189.
Tab le 1 Clinical scales for the diagnosis of PTS.
PTS scale Criteria used to d iagnose PTS
CEAP 89 Patients with chronic venous disease classified into 1 of 7 clinical classes 
(class 0-6) according to presence of clinical signs; each class may include 
signs present in lower-order class
Class:
0. Symptoms only; no visible or palpable signs of venous disease
1. Telangiectasias, reticular veins, malleolar flare
2. Varicose veins
3. Edema, no skin changes
4. Skin changes
4a. pigmentation or eczema
4b. lipodermatosclerosis or atrophie blanche
5. Skin changes with healed ulcer
6. Skin changes with active ulcer
Each clinical class is then subclassified as to:
Etiology (congenital, primary, secondary)
Anatomy (superficial, deep, perforator veins)
Pathophysiology (reflux, obstruction or both)
Villalta 10 5 symptoms (pain, cramps, heaviness, pruritus, paresthesia)
6 signs (edema, skin induration, hyperpigmentation, venous ectasia, 
redness, pain during calf compression)
Each rated as 0 (absent), 1 (mild), 2 (moderate), or 3 (severe)
Points are summed 
Total score:
0-4: no PTS
5-14: m ild/moderate PTS 
> 15 or presence of ulcer: severe PTS
13
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The CEAP classification has been developed by the American Venous Forum 
in co-operation with the European societies of Phlebology to obtain comparison  
of diagnosis and treatment in patients with venous diseases8. The major 
disadvantage of the CEAP classification is that clin ical components are 
relatively static over time and description of subtle changes is limited. However 
the CEAP classification has been w idely implemented as a descriptive means 
of categorizing patients. The Villa lta scale, based on symptoms and clinical 
signs has recently been recommended as a standard to define PTS for use in 
clinical investigations by the Scientific and Standardization Committee of the 
International Society of Thrombosis and Haemostasis1011.
P a th ophys io lo g y  o f PTS
It is generally hypothesized that PTS develops as a result of the combination  
of venous hypertension, due to persistent outflow obstruction and/or valvular 
incompetence, with abnormal m icrovasculature and lymphatic function. In 
previously thrombosed veins more reflux develops than in non-thrombosed  
veins. It was found that DVT was often accompanied with the development of 
reflux in thrombosed segments which in its turn was associated with increased 
risk of PTS1213. Persistent obstruction as a single entity leads to PTS in only 
a m inority of patients. The combination of reflux and persistent venous 
obstruction results in the highest risk of PTS14,15. The combination is probably 
caused by incomplete recanalization, fibrosis of the veins or a paucity of 
collaterals.
Venous hypertension is the net result of persistent obstruction and reflux. 
Depending on the height of the person the hydrostatic pressure in the venous 
system of the leg is approximately 80-90 mmHg and derives from the weight 
of the blood column below the right atrium. This pressure is reduced while 
walking when skeletal muscle contractions transiently increase pressure 
within the deep veins and, with competent venous valves, venous blood flows 
towards the heart. The pressure in the venous system is subsequently reduced 
to 30 mmHg or lower in 7 to 12 steps1617. In the absence of competent valves 
the decrease in venous pressure is attenuated. It seems likely that in PTS 
venous pressure becomes higher and remains elevated for a prolonged period 
of time (see figure 5). Through incompetent perforator veins this elevated 
venous pressure is transm itted to the superficial system and to the m icrocircu­
lation of the skin, resulting in skin changes as described in patients with PTS. 
In a sample of 360 lower limbs of patients with a w ide spectrum of venous 
diseases, there was a linear trend towards more severe skin damage with 
increasing ambulatory venous pressure18.
14
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F igu re  5 Action of the musculovenous pump in lowering venous pressure in 
the leg. After prolonged standing, venous pressure in the foot is 
approximately 90 mmHg in both a patient with incompetent venous 
valves and a person with a normal leg. During walking, the 
musculovenous pump rapidly lowers the venous pressure in the 
normal leg but is ineffective in the leg with valvular incompetence.
--------------- 1--------------- 1--------------- 1--------------- r
0 10 20 30 40
Seconds
(Reproduced from Coleridge Smith17 with the permission of the publisher)
2. Techniques to investigate the venous system
Several techniques can be used to investigate the venous system. To understand 
the explanation of these techniques it is important to have knowledge of the 
anatomy of the normal venous system.
The venous  sys tem
The venous system of the lower extrem ities includes the deep veins, which lie 
beneath the muscular fascia and drain the lower extrem ity muscles. The 
superficial veins above the deep fascia drain the cutanous m icrocirculation  
(see figure 6 en 7) 19. Perforating veins drain the superficial bloodflow into the 
deep system.
15
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F igu re  6 Superficial and perforating veins of the leg19.
The shape of the venous wall depends greatly on pressure, volume and flow. 
The venous system has a large capacity. Large changes of volume lead to a 
minimal change in pressure over the normal range of 5 to 25 mmHg. Depending 
upon posture and activity, 60 to 80% of the resting blood volume resides in the 
venous system. Normally, at the end of the venous capillary the pressure is 12 
to 18 mmHg and falls steadily toward atrial pressures of 4 to 7 mmHg. Venous 
return is achieved by the ejection of blood by the lower extrem ity muscle 
pumps, especially the calf muscle pump, assisted by competent valves. 
Bicuspid valves in deep, superficial and perforating veins assure unidirectional 
flow in the normal system and prevent retrograde venous flow20.
16
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F igu re  7 Deep veins of the leg19.
Either invasive or non-invasive measurement techniques can be employed to 
document and quantify the presence of obstruction, reflux, or both. In former 
studies, performed in our hospital, especially plethysmographic methods and 
duplex was used to investigate PTS12,13. It should be noted that different tests 
provide answers to different questions: some tests provide information about the 
anatomy of the venous system, and others provide haemodynamic information.
A na tom ica l in ve s tig a tio n s
Ascending phlebography
In the past ascending phlebography has been the method of choice to 
demonstrate patency of the veins, define the anatomy, and help to distinguish  
between primary and secondary venous insufficiency. It is still used as the 
‘ ’gold standard ’’ to establish the accuracy of new investigations that determine
17
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the presence or absence of disease or its anatomic extent21. Since this method 
is invasive, its current application is lim ited to cases in which duplex scanning  
is unavailable, inadequate or equivocal.
Descending phlebography
The aim of descending phlebography is to demonstrate reflux in either the 
superficial or deep veins and to determ ine the point of leakage from the pelvis 
to the lower limbs and from deep to superficial veins. It is also used to provide 
information on the anatomic localization and morphology of the venous valves, 
assess the extent of reflux, delineate the venous anatomy in complex cases, 
and differentiate primary from secondary venous insuffic iency22.
Duplex scanning
Duplex has been used since the early 1980s to diagnose DVT. Its use has been 
extended to detect obstruction (by residual thrombosis) or reflux and to determine 
the anatomic extent in chronic venous insufficiency and in the follow-up of DVT. 
Color flow duplex imaging provides instant visualization of blood flow and its 
direction, has decreased examination time and improved the accuracy23.
In former studies we measured the presence and extent of residual thrombus 
as the throm bosis score (TS) using duplex. The vein segments examined 
were the common femoral vein, the femoral vein (proximal and middle), the 
great saphenous vein (proximal, m iddle and distal), the popliteal vein, the 
short saphenous vein, the posterior and anterior tib ia l veins, the peroneal 
and gastrocnem ial veins. In the calf each artery is accompanied by 2 veins; 
these were numbered: 1 being the most superfic ia l and 2 the deeper vein24.
Compressibility was assessed in the transverse plane with gentle pressure 
applied to the overlying skin by the duplex-probe. In the longitudinal plane the 
presence of the Doppler signal was measured. In the proximal veins a 
spontaneous Doppler signal is usually present. In the distal veins a flow signal 
was considered present after gentle squeezing the extrem ity below the level of 
measurement. The definition of the TS was based on the description of extent 
of thrombus and site involvement by Porter et al8. A vein segment was 
considered occluded when the vein segment was non-compressible and no 
Doppler signal was found (TS=2) and non-occluded if it was not completely  
compressible but flow was present (TS=1). A fu lly patent vein segment showed 
complete compressib ility and flow (TS = 0). TS values were calculated by 
counting the TS values of the 10 vein segments. The kappa-coefficient of the 
interobserver variability of the duplex measured TS was 0.7724.
18
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H aem odynam ic  in ve s tig a tio n s
Ambulatory venous pressure
Ambulatory venous pressure (AVP) measurement is based on the original 
observation that the venous pressure in the foot decreases during walking and 
gradually returns to the resting value when walking stops. Venous pressure is 
measured by inserting a needle into a vein on the dorsum of the foot; the 
needle is then connected through a pressure transducer and an amplifier to a 
potentiometric pen recorder. The patient performs a standard exercise of 10 
tip toe movements or knee bends at the rate of 1 per second. At the end of the 
exercise the patient remains motionless while the recovery of the pressure to 
baseline level is recorded in seconds. The exercise is subsequently repeated 
while the superficial venous system is occluded to measure only the deep 
venous system. AVP is regarded as the reference standard to measure venous 
hypertension25 26.
Photoplethysmography and Light reflection rheography 
Photoplethysmography and Light reflection rheography are noninvasive 
techniques that can detect local changes in the blood content of tissues. The 
principal application is to study blood flow and blood volume changes in the 
skin. A probe that consists of a light source and a light-sensitive diode is 
positioned on the skin. The backscatter of light detected with the light-sensi­
tive diode is affected by changes in the number of red blood cells in the dermis. 
The venous plexus becomes less full and light absorption decreases as the 
venous pressure falls with exercise2728.
Ambulatory strain gauge plethysmography (ASGP)
Calf volume changes during exercise can be detected with strain gauge, and 
comparison with AVP measurements was performed earlier. It is used to 
measure calf volume changes in the upright position w ithout the need to 
change position from the supine to upright. Strain gauges are applied to both 
ankles above the malleolus. They are electrically calibrated in situ to percentage 
volume change (mL/100mL). The preferred exercise is 20 knee bends. After 
the exercise the patient must stand completely still until full-volume restitution 
takes place. The plethysmographic recording allows calculation of venous 
refilling time and expelled volume. The second part of the examination involves 
the application of a below knee compression cuff that is 2.5 cm w ide and 
inflated to a pressure of 70 mmHg. In patients w ith isolated superficial venous 
reflux, this compression will normalize the venous return time. ASGP is used to 
quantify the performance of the venous muscle pump in terms of venous reflux 
and expelled volume. It may differentiate superficial from deep venous
19
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insufficiency, but it cannot precisely localize the site and extent of the reflux or 
obstruction in either system29.
The supine venous pump function test (SVPT) can be used to measure calf 
muscle pump function30. The patient lies in a supine position, with the knees 
slightly bent and supported by foam pads. The feet rest against a foot support, 
at an angle of approximately 60°. A pneumatic cuff is applied to each thigh. 
Mercury in rubber strain gauges are wrapped around the lower leg. The 
measurement starts with inflation of the cuffs to a constant pressure of 70 
mmHg. This results in a gradual venous pressure increase, the concom itant 
volume increase is registered by the plethysmograph. During venous 
congestion standardized foot movements are performed. This muscle pump 
action causes blood to be squeezed underneath the cuff and thus the volume 
of the limb decreases. In the period of rest after the exercise and still during 
congestion, the volume returns to its maximum level, and the expelled volume 
can be measured. This exercise is being performed at different cuff pressures. 
Additionally a pressure-volume relation is determ ined. For this purpose the 
maximum volume increases (Vc) are measured at pressures of 80, 60, 40, 30 
and 20 mmHg. By plotting the Vc-values against the venous pressure a curved 
pressure-volume relation is found which is characteristic of the limb volume 
distensibility. By using this pressure-volume relation it is possible to convert 
the expelled volume into a pressure decrease.
Venous outflow resistance (VOR)
Venous outflow is evaluated by the use of the venous occlusion technique with 
the patient in supine position, with the knees slightly bent and supported by 
foam pads. A thigh tourniquet is placed as proximally as possible and inflated. 
Venous volume increases to a new plateau. The tourniquet is then deflated 
suddenly and the venous outflow curve is recorded. Venous outflow resistance 
(VOR) can be calculated from the outflow curves for volume and pressure 
obtained simultaneously. By using several cuff pressures (50 to 15 mmHg) a 
relationship is obtained between congestion pressure and venous outflow, 
which results in analogy to Ohm’s law, in a value for the outflow resistance of 
the venous system. The VOR is expressed in resistance units: mmHg*min/%. 
In a previous study a VOR exceeding 0.8 mmHg*min/% was considered  
abnormal. The non-thrombotic leg was used as control. The reproducib ility of 
the VOR was within 10%31.
20
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F igu re  8 Venous outflow resistance: the position of the patient.
Air plethysmograhy
The air plethysmograph consists of a 35 cm long polyurethane tubular air 
chamber that surrounds the entire leg. The air chamber is inflated with air and 
the connection to the air circu it is used for calibration. Changes in the volume 
of the leg as a result of filling or emptying of veins produce corresponding  
changes in the pressure of the air chamber. Thus, leg volumes can be measured 
in m illiliters according to the calibra tion32.
Duplex (quantification of reflux)
Duplex ultrasound techniques detect reflux in individual veins, whereas 
plethysmographic methods measure reflux in the entire leg. In our studies 
reflux was measured in the longitudinal plane. To provoke reflux the Valsalva 
manoeuvre was used in the proximal veins and manual compression with 
sudden release in the distal veins. Pathological reflux was defined as a reversed 
flow duration of more than 1 second in the proximal veins and more than 0.5 
second in the distal veins. The kappa-coefficient of the interobserver variability 
is 0.8624.
21
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Several studies have described the association of measurements with the 
above mentioned techniques and the development of PTS. Nevertheless, the 
predictive value of these measurements in the first months after DVT for PTS 
is unclear.
In the studies presented in this thesis the measurement techniques used are 
venous outflow resistance and the supine venous pump function test with 
strain gauge plethysmography. Furthermore TS (reflecting the presence of 
residual thrombosis) and reflux were measured with duplex scanning.
3. Inflammation in DVT and PTS 
In flam m a tio n  and DVT
Clinically it is apparent that most patients with deep vein thrombosis manifest 
the four core signs of inflammation, namely heat, redness, pain and swelling. 
In contrast w ith arterial throm bosis relatively little is known about the 
relationship between venous thrombo-embolism  and inflammation.
Prediction of future VTE
Two large prospective studies examined the predictive value of plasma CRP 
levels for the development of DVT. In the Physicians Health Study 22.071 male 
physicians were enrolled and followed for up to 14 years. Mean plasma CRP 
levels in subjects who developed VTE (n=101) were 1.24 mg/l compared with 
1.10 mg/l in subjects who did not develop VTE (p=0.34). In 19.237 men and 
women w ithout previous DVT from two pooled population based cohort 
studies, 159 VTE events occurred during 8 years of follow-up. No significant 
associations were found between baseline CRP and the subsequent 
development of VTE. Both studies indicate that plasma CRP levels do not 
appear to predict future DVT events33,34.
In the Norwegian Health Study with 66.140 participants, 506 participants were 
diagnosed with a first VTE in years of follow-up. Several levels of interleukins 
(IL-1P, IL-6, IL-8, IL-10 and IL-12p70) and tumor necrosis factor-a (TNF- a) were 
measured. While Odds ratio’s ranged from 0.9 to 1.1, no evidence was found 
for a relation between VTE and inflammation35.
Diagnosis of VTE
The utility of CRP to diagnose or exclude DVT was evaluated in four studies in 
patients w ith clinical suspicion of DVT. A small study in 47 patients suggested
22
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that non-elevated levels of CRP could be used to rule out DVT36. Three larger 
studies in 78, 150 en 132 patients were conflicting with the the first study37-39. 
Combining the results of these four studies yielded a pooled weighted  
sensitiv ity of 77%, specific ity of 66%, positive predictive value of 53% and 
negative predictive value of 85%40. Therefore CRP is not useful in excluding 
DVT.
Markers of inflammation after DVT
Several markers of inflammation have been measured in patients with DVT 
compared with controls w ithout DVT. In a case-control study in patients with 
recurrent DVT there was a higher prevalence compared to controls of elevated 
interleukin-6 (IL-6), interleukin-8 (IL-8) and monocyte chemotactic protein 
(MCP-1) even up to several years after the acute event41. In patients with 
elevated plasma concentrations of these inflammatory markers the risk of VTE 
was 2 to 3 fold increased. A concentration-dependent relationship of DVT was 
found with IL-8 and MCP-1 concentrations. In the Leiden Thrombophilia study 
(474 DVT-patients and 474 controls) CRP-levels were higher in patients than in 
controls (1.49 vs 1.12 mg/l)42. Moreover, patients were more likely to have 
elevated Tumor Necrosis Factor (TNF)-a, IL-6 and IL-8 levels than those 
without DVT. Levels of inflammatory markers were not related to the time 
interval between the final throm botic event and the time of blood sampling. 
The possib ility that the inflammatory state preceded the DVT was not ruled out 
nor established. High levels of the anti-inflammatory cytokine IL-10 were 
associated with a lower risk of VTE (OR 0.4, 95% 0.2-1.3)43. Overall, these 
findings suggest that inflammation plays a role in the pathogenesis of DVT.
In flam m a tio n  and PTS
Since thrombosis and inflammation are related, it can be hypothesized that 
inflammation in DVT is also involved in the development of PTS. Most of the 
studies supporting evidence for this hypothesis are animal models with 
stasis-induced thrombosis. From these studies it is known that after venous 
thrombosis an inflammatory response occurs both in the vein wall and in the 
thrombus mass, and leads to thrombus amplification, organization and vein 
recanalization.
In response to thrombosis elevated plasma concentrations of TNF, IL-6, IL-10 
and MCP-1 were measured with a peak after 1 to 48 hours44. An early neutrophil 
infiltration into the vein wall was followed by extravasation of monocytes/ 
macrophages and lym focytes which depends on a cytokine/chemokine  
gradient. Neutralization of the anti-in flammatory cytokine IL-10 increased
23
CH APTER 1
thrombosis-associated vein wall inflammation, while exogenous supplementa­
tion of IL-10 decreased thrombus-associated vein wall inflammation with 
concom itant reduction in thrombotic activity45. Selectins (P- and E-selectin) 
are also involved in this inflammatory process. Inhibition of P-selectin limits 
vein wall neutrophil extravasation and is equally effective in vein recanalization 
as treatment with LMWH4647. The perivenous inflammation can be detected 
as a bu ll’s eye sign w ith Gadolinium enhanced Magnetic Resonance 
Venography48.
For early thrombus resolution neutrophils are important by promoting  
fibrinolysis and collagenolysis. In a rat stasis model, neutropenia was 
associated with larger thrombi after 2 and 7 days and was correlated with  
increased thrombus fibrosis49. For later DVT resolution monocytes are probably  
the most important cells. Correlated with elevated MCP-levels, monocyte influx 
peaks 8 days after thrombogenesis50. Monocytes are recruited into maturing 
thrombi and increasing numbers in the thrombus enhance its resolution51.
Elastinosis and collagenolysis seem to occur early, but later increased vein 
wall collagen has been observed leading to late fibrosis52 53. The vein wall 
fibrosis ultimately may lead to alterations in the vein wall compliance and valve 
dysfunction. Inhibition of the inflammatory response with anti-P-selectin 
decreased vein wall injury and fibrosis independent of thrombus size47.
In conclusion, in animal models it is shown that DVT leads to a inflammatory 
response of the thrombus and vein wall. A lthough it promotes DVT resolution 
it may lead to vein wall injury and fibrosis. So far, no studies have been 
performed in DVT-patients to examine the role of inflammation in the acute 
phase of DVT and in the development of PTS.
4. Obesity as risk factor for the development of PTS
Several risk factors of PTS have been identified in the past. These can be 
classified in determ inants present at diagnosis, like age, sex, proximal location 
of DVT, varicose veins and thrombophilia , and determ inants during follow-up  
of DVT, like residual thrombus, persistent elevation of D-dimer and recurrent 
DVT54. It should be noted that many studies show conflicting results and the 
relevance of the determ inants varies between the different studies54 55. For 
example, male gender was a predictor of PTS56, while in other studies the 
opposite was seen5758. An insufficient quality of oral anticoagulant therapy
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fo llow ing the acute thrombotic episode is associated with an increased risk of 
PTS59. The most important risk factor for PTS is ipsilateral recurrent DVT58 59. 
Several studies reported an association between obesity and the development 
of PTS. The first studies were small and in specialized patient groups (young 
women)60 61. Studies in larger patient groups confirmed these results56-59, 62. 
Still, the importance of obesity as a risk factor for PTS and the nature of the 
relationship both remain unclear.
This is important as obesity is also related with a higher risk of DVT itself. In 
the Multiple Environmental and Genetic Assessment of risk factors for VTE 
study, the risk of VTE was two to three fo ld increased in obese patients, 
especially in women using oral contraceptives63. Recently a meta-analysis 
showed that in nine studies with 8125 thrombosis patients and 23 272 controls, 
obesity was associated with an OR of 2.33 (95% CI 1.68-3.24) for VTE64. In 
addition, a linear relationship was found between excess body weight and 
recurrent DVT65.
Relevant is the increasing incidence of overweight and obesity worldw ide. The 
most recent incidence of obesity in the US is estimated 32% among men and 
35% among women66. In the Netherlands the incidence of overweight increased 
from 37% in 1981 in males to 51% in 2004 and in females from 30% to 42%. In 
2004 obesity was estimated to be present in 10% of adult males and in 12% of 
females67.
In conclusion, since obesity is increasing in incidence and is a risk factor for 
VTE, it is relevant to examine the importance of obesity as a risk factor for 
PTS.
5. Bandaging in the prevention of PTS
Compression bandaging and elastic stockings
The only evidence based preventive measure of PTS is the use of sized-to-fit 
graded compression stockings which reduces the rate of PTS by about 50%. 
The first study on the effect of elastic compression stockings (ECS) was 
performed by Brandjes et al68. Patients with a first episode of proximal DVT 
were randomized between treatment with compression stockings (30-40 
mmHg, n=96) or w ithout stockings (n=98) for at least two years. Mild-to- 
moderate PTS occurred in 20% of the stocking group and in 47% of the control 
group and severe PTS in respectively 11% and 23%, so a reduction of 50% was
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achieved. A second randomized trial by Prandoni in 180 patients with DVT 
confirmed these results. PTS was diagnosed after two years in 25% in the 
stocking group and 49% in the control group69. In a systematic review it was 
shown that ECS not only reduced the incidence of any PTS but also of severe 
PTS with an Odds ratio of 0.31 and 0.39 respectively70. This review included  
the results of a third study performed by Ginsberg (who used a different 
study-design with randomization one year after diagnosis of DVT). In these 47 
patients with valvular insufficiency but no complaints 0 of 24 patients with 
active stockings and 1 of 23 patients with placebo stockings developed PTS. 
The contrast in results can be explained by inclusion of asymptomatic patients 
with a lower risk of PTS in the latter study and the delay in the use of ECS of 
one year71.
Uncertainty remains regarding the tim ing to start compression therapy. In the 
study of Brandjes et al68 and Prandoni et a l69 the stockings were applied two to 
three weeks after the thrombotic event and one week after reduction of edema. 
There is only one trial comparing immediate compression therapy and walking 
with no compression and bedrest72. 45 Patients with proximal DVT were 
divided in 3 groups i.e. 15 patients with inelastic compressive bandages, 15 
patients with th igh-length compression stockings and 15 patients who 
underwent bed rest and no compression. Pain and leg circumference improved 
better in the compression groups compared w ith the bed rest group and there 
were no differences in incidence of pulmonary embolism and progression of 
thrombi in the first ten days. Despite lack of evidence on this matter it has 
become tradition in Europe to treat patients with inelastic compressive 
bandages and early ambulation although the effect of immediate compression  
bandaging after DVT on the development of PTS is unclear.
A im  o f th e  th e s is
In this thesis the most important aim was to study the role of inflammation in 
the development of PTS. Moreover we focused on other aspects of PTS: the 
predictive value of non-invasive venous examinations, the treatment effects of 
immediate compression therapy and the effect of BMI as a risk factor for 
PTS.
The follow ing questions were formulated:
1) What is the predictive value of non-invasive venous examinations like 
duplex and strain-gauge plethysmography for the development of PTS?
2) What is the role of inflammation in DVT and PTS?
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3) What is the influence of obesity on the development of PTS and what is the 
nature of this relationship?
4) What is the role of immediate compression bandaging in the prevention of 
PTS?
O u tlin e  o f the  th e s is
To investigate the above research questions the follow ing studies were 
performed:
In chapter 2 we prospectively studied the clinical incidence of PTS in a six year 
fo llow-up study. The predictive value of non invasive haemodynamic tests 
shortly after DVT was determ ined by measuring the amount of obliterated  
veins, reflux, venous outflow resistance and calf muscle pump function.
In chapter 3 we studied whether an inflammatory response occurred in the 
acute phase of DVT with IL-6, IL-8 and CRP as inflammatory markers. Plasma 
concentrations were measured on the day of adm ission (day 0) in patients with 
acute DVT and in 33 controls. In patients with DVT inflammatory markers were 
also examined on five subsequent days.
In chapter4 we investigated whether inflammatory markers and D-dimer in the 
acute phase of DVT are associated with the gradual development of elevated 
venous outflow resistance, more thrombosed veins (thrombosis score) during 
a 90 days fo llow-up and the development of clinical PTS after one year in 110 
patients with a first DVT.
In chapter 5 the effect of obesity is investigated on several predictors of PTS 
to obtain insight in the pathophysio logy of the relationship between obesity 
and PTS. We performed a meta-analysis of studies assessing the influence of 
BMI on PTS. Aim was to examine the importance of obesity as a risk factor for 
PTS.
In chapter 6 we investigated the influence of immediate compression therapy 
in the acute phase of DVT on the development of the PTS after one year. 
Patients with DVT were randomized to immediate bandaging or no bandaging  
before elastic stockings were applied. Patients were examined with non-invasive 
examinations like the venous outflow resistance (VOR), thrombosis score (TS) 
and reflux and evaluation of PTS.
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Abstract
O b jec tive
The ability to predict severity of the post-thrombotic syndrome (PTS) early 
after acute deep vein thrombosis (DVT) is limited. The aim of our study was to 
examine the incidence of PTS prospectively and to evaluate the predictive 
value of non-invasive venous examinations shortly after DVT for the 
development of PTS.
M e thods
In 93 patients with DVT thrombosis score (TS), reflux, venous outflow resistance 
(VOR) and calf muscle pump dysfunction (CMP) were examined prospectively. 
After one, two and six years patients were evaluated for PTS using the clinical 
scale of the CEAP-classification (PTS present > 3 on a scale from 0 to 6). Area 
under the curves (AUC) were used to evaluate the predictive value of the 
non-invasive examinations at one and three months after diagnosis of DVT for 
future PTS.
Resu lts
The cumulative incidence of PTS increased from 49% (32/65) after one year to 
55% (36/65) and 56% (27/48) after two and six years, whereas the incidence of 
patients with PTS class 4 progressed from 20% after two years to 33% after six 
years. The prognostic value to predict PTS was highest for the combination of 
TS, VOR and reflux measured three months after diagnosis and showed an 
AUC of 0.77 (0.65-0.90) for PTS after one year.
C onc lu s ion
The incidence of PTS after DVT did not increase significantly after one year, 
whereas during longer fo llow-up the severity of PTS rose in patients with PTS. 
Moreover, measurement of TS, VOR and reflux three months after DVT could 
predict, with reasonable accuracy, the risk of PTS after one year of follow-up.
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Introduction
The post-thrombotic syndrome (PTS) is a frequently occurring chronic 
complication of deep vein thrombosis (DVT)12 with a cumulative incidence of 
20-50%. Because DVT is relatively common (1 to 1.6/1000 per year)3, PTS has 
significant morbidity and socio-economic consequences4. It was estimated 
that health care costs of treating the post-thrombotic complications mounts 
up to 75% of the costs of treatment of primary DVT5. The pathogenesis of PTS 
is not completely understood, but it is suggested that persistent obstruction 
and the development of valvular insufficiency after DVT leads to venous 
hypertension, resulting in symptoms like pain and swelling of the leg and signs 
like edema, hyperpigmentation and the occurrence of venous ulcers. Although 
it was generally considered to take five to ten years to develop PTS, the current 
opinion is that PTS already becomes clinically manifest within two years 
following the acute thrombotic event6. However, there are only scarce data 
reported on the incidence and progression of PTS over time during longer 
prospective follow-up studies.
To reduce the incidence of PTS it would be desirable to identify determinants 
to select patients at risk for PTS as early as possible and to evaluate the 
effectiveness of and the indications for prophylactic interventions. Classification 
of PTS was better predicted by determinants like, for example, the rate of 
recanalization during 8 to 110 months follow-up than by features documented 
at presentation like, for example, the initial extent of thrombosis7. At present, 
the ability to predict the severity of PTS in an early stage is limited.
Results from non-invasive venous examinations, such as strain gauge plethysmo­
graphy and duplex scanning of the legs, may be useful as predictors of the 
development of PTS. In the follow-up of patients after acute DVT, strain gauge 
plethysmography can measure venous outflow resistance (VOR) and calf muscle 
pump function (CMP). VOR is increased in DVT and declines in the first months 
after DVT to high normal levels8. CMP was decreased in 57% of the patients in a 
retrospective study seven to thirteen years after DVT. The difference in CMP 
between the thrombotic and the non-thrombotic leg was related to the different 
classes of PTS9. Moreover, with duplex scanning it is possible to measure both 
the extent of thrombus in different veins (thrombosis score) and reflux as a result 
of valvular insufficiency. In two studies the rate of complete resolution of thrombus 
after six to nine months was 57%10-11. Although several studies described the 
association of measurements like VOR, CMP, TS and reflux for the development 
of PTS, the predictive value of these measurements in the first months after DVT
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for PTS is unclear. The aim of this study was to examine the incidence and 
evolution of PTS prospectively and secondly to evaluate the predictive value of 
non-invasive venous examinations for the development of PTS.
Methods
Patien ts  and s tu d y  design
Between 1995 and 1998, 93 consecutive patients with proximal and/or distal DVT, 
proven by echography or phlebography, were eligible for the study. The study 
was approved by the local ethics committee and all included patients gave 
informed consent. Follow-up visits and non-invasive examinations were planned 
after one, three and six months, and one, two and six years. Previous thrombosis 
in the ipsilateral leg was a criterion for exclusion. DVT was defined idiopathic in 
the absence of malignant disease, trauma of the leg, surgical procedures, 
immobilization or pregnancy within six months, in all other cases including 
oestrogen use DVT was defined secondary. Patients were treated with intravenous 
heparin or Low Molecular Weight Heparin (LMWH) and oral anticoagulants 
(acenocoumarol or fenprocoumon) for at least three months. In all patients 
bandages were applied and after reduction of edema sized-to-fit graded elastic 
stockings were prescribed. The stockings prescribed were class III (40 mmHg) 
thigh-length in case of proximal DVT and knee-length in case of distal DVT. Patients 
with arterial insufficiency or above 75 years of age, a class II (30 mmHg) stocking 
was prescribed. Patients were instructed to wear the stockings for at least one year. 
Symptomatic recurrent DVT was objectively confirmed with venography.
D eterm ina tion  o f PTS
After one, two and six years patients were evaluated by a dermatologist who 
was unaware of the results of the venous examination. The severity of PTS was 
scored according to the clinical score (range 0-6) of the CEAP classification 
(Clinical, Etiologic, Anatomic, and Pathofysiologic)12. In this classification 
patients with class 0 represent no visible or palpable signs of venous disease 
symptoms of PTS; class 1 telangiectases, reticular veins or malleolar flare; 
class 2 varicose disease; class 3 edema without skin changes; class 4 skin 
changes ascribed to venous disease (pigmentation, lipodermatosclerosis); 
class 5 skin changes with a healed ulcer and class 6 skin changes with active 
ulceration. PTS was defined present if the classification was 3 or more.
N on-invasive  venous m easurem ents
The VOR was measured in both extremities by strain-gauge plethysmography 
as described previously13-14. The patients were examined in supine position
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with pneumatic cuffs around the thighs and strain gauges around the calves. 
After inflation of the cuffs the venous volume increases gradually. When 
maximum volume was achieved, release of cuff-pressure resulted in a volume 
decrease measured by plethysmography. The tangent to the slope of the 
volume decreased was drawn 0.5 seconds after pressure release and the 
slope was converted into a venous emptying rate (VER). This procedure was 
performed at 5 different cuff pressures (50 to 15 mmHg). Subsequently, the 
corresponding VER values were plotted against the effective cuff pressures. 
The slope of the line through the points gave an angle p. In analogy with Ohm’s 
law the VOR is calculated as 1/tangent p. The VOR value is expressed in 
resistance units: mmHg*min/%. In a previous study a VOR exceeding 0.8 
mmHg*min/% was considered abnormal. The non-thrombotic leg was used as 
control. The reproducibility of the VOR was within 10%14.
The calf muscle pump function was tested with the use of the supine venous 
pump function test (SVPT) performed by strain gauge plethysmography. The 
strain gauges were placed below the muscular parts of the calf to minimize 
motion artefacts. After maximum volume increase the patient was instructed 
to perform maximal dorsal and plantar flexion of the feet 10 times in 20 
seconds. This procedure was performed twice and repeated at different cuff 
pressures of 50, 60 and 70 mmHg. Using the volume pressure-relationship the 
decrease in volume during exercise is converted to a decrease in pressure, 
which is expressed as a percentage of the initial pressure. The average 
pressure change at all the different cuff pressures in healthy individuals is 60% 
or more. The coefficient of variation is 9%15.
Duplex examinations were performed by two experienced vascular technicians 
with a Toshiba SSA 270A scanner with a 3.75 or 5 MHz probe in low flow 
setting. The examination was performed with the patient in a reverse 
Trendelenburg position at 45 degrees, the knees flexed and with the feet 
resting on a foot-support. 16 Vein segments were examined: the common 
femoral vein, the superficial femoral vein (proximal and middle), the long 
saphenous vein (proximal, middle and distal), the popliteal vein, the short 
saphenous vein, the posterior and anterior tibial veins, the peroneal and 
gastrocnemial veins. In the calf each artery is accompanied by 2 veins; these 
were numbered: 1 being the most superficial and 2 the deeper vein. The distal 
superficial femoral vein is often not compressible because of the anatomical 
position in the canal of Hunter. After the third month the peroneal, gastrocnemial 
veins and tibial anterior veins were not examined because many veins could 
not be traced and these measurements appeared very time-consuming. The
37
CH APTER 2
results of the remaining 10 vein segments were used for analysis. The com­
pressibility was assessed in the transverse plane with gentle pressure applied 
to the overlying skin by the duplex-probe. In the longitudinal plane the presence 
of the Doppler signal was measured. In the proximal veins a spontaneous 
Doppler signal is usually present; in the distal veins a flow signal was 
considered present after gentle squeezing the extremity below the level 
of measurement. The definition of the thrombosis score (TS) was based on 
the description of extent of thrombus and site involvement by Porter et al12. 
A vein segment was considered occluded when the vein segment was non- 
compressible and no Doppler signal was found (TS=2) and non-occluded if it 
was not completely compressible but flow was present (TS = 1). A fully patent 
vein segment showed complete compressibility and flow (TS = 0). TS values 
were calculated by counting the TS values of the 10 vein segments. The kappa- 
coefficient of the interobserver variability was 0.7716.
Reflux was measured in the longitudinal plane. In the proximal veins the 
Valsalva manoeuvre was used to provoke reflux and in the distal veins by 
manual compression with sudden release. Pathological reflux was defined as 
a reversed flow duration of more than 1 second in the proximal veins and more 
than 0.5 second in the distal veins. The kappa-coefficient of the interobserver 
variability is 0.8616.
S ta tis tica l ana lys is
Receiver-operating characteristic (ROC) curves were used to evaluate the 
prognostic value of the different non-invasive examinations as a single test in 
predicting PTS after one, two and six years. The predictive value of several 
combinations of these examinations was tested. Using a logistic regression 
model the strength of the covariates and outcome (PTS) was determined. 
The new marker was defined as P1X1 + P2X2 (+ P3X3). Statistical analysis was 
performed with SPSS software.
Results
Ninety-three patients were included in the study. During follow-up 19 patients 
died. Malignancy was the cause of death in five patients. 27 Patients withdrew 
consent or were unable to continue follow-up in the study. The number of 
patients who completed follow-up after one, two and six years was 65, 65 and 
48, respectively. Patient characteristics are summarized in table 1.
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DVT was idiopathic in 39 (42%) patients and secondary in 54 (58%) patients 
(respectively, malignant disease 17, recent operation 12, recent trauma 5, 
immobilization 15 and pregnancy or puerperium 5 patients). DVT extended 
into the superficial veins in 31% of the patients. In 21 patients the short 
saphenous vein was occluded and in 8 patients parts of the long saphenous 
vein. Recurrent DVT was diagnosed in 21 patients with a median interval of 6 
months (0.5-47), of whom 11 patients had ipsilateral recurrent DVT.
Table 1 Clinical characteristics of the study patients at diagnosis of deep vein 
thrombosis (DVT).
All patients 
N =93
2 year
fo llow -up
N =65
6 year
fo llow -up
N = 48
Male : female 47 : 46 35 : 30 28 : 20
Age at d iagnosis (years) 53 (17-89) 51 (17-88) 49 (23-78)
Site of DVT: proxim al/distal 79 : 14 53 : 12 40 : 8
Left : right leg 56 : 37 38 : 27 27 : 21
Previous DVT (contralateral) 7 6 4
Recurrent DVT:
Ipsilateral 10 10 6
Contralateral 5 4 1
Both ipsi and contralateral 1 1 0
Pulmonary embolism 3 2 0
Of the 93 patients enrolled in the study follow-up was completed in 65 patients after two years 
follow-up and 48 patients after six years of follow-up.
The incidence of PTS (CEAP > 3) increased from 49% after one year to 55% 
after two years, but without further increase after six years (56%) (Figure 1). 
The incidence of patients with PTS class 4 progressed from 20% after two 
years to 33% after six years. There were no patients diagnosed with PTS CEAP 
5 or 6. The incidence of PTS class 4 after six years was higher in patients with 
ipsilateral recurrent DVT compared to other patients (71% and 27%, 
respectively).
Despite the advised duration of compression stocking for one year, 20% used 
them for a shorter period. Patients wore mostly knee-length stockings (81%, 
thigh-length stockings 19%) with a pressure of 40 mmHg in 85% of the cases
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F igure  1 Incidence of patients with the post-thrombotic syndrome (CEAP > 3) 
during follow-up.
100%
80%
60%
40%
20%
□ ceap 0/1
□ ceap 2
□ ceap 3
□ ceap 4
1 year 2 years 6 years
Class 0/1 no signs of venous disease or telangiectases, reticular veins or malleolar flare; class 2 
varicose disease; class 3 edema without skin changes; class 4 skin changes ascribed to 
venous disease (pigmentation, lipodermatosclerosis); class 5 and 6 (healed) ulcer not present.
and 30 mmHg in 15%. Good compliance (> 6 days/week) was reported by 
85%. At follow-up after six years, compression stockings were worn regularly 
by 20 (42%) of all patients mostly because of complaints of PTS. In patients 
with PTS, stockings were used by 19 (70%) of the patients. Anticoagulation 
was continued for 3 months in 46% of the patients, 6 months in 28% and for 
longer than a year in 26%. In PTS-patients, mean INR-levels were not different 
compared to patients without PTS (2.79 [SD 0.48] vs 2.59 [SD 0.44]).
VOR declined in the first three months of treatment from 1.42 mmHg*min/% in 
the first few days after diagnosis to 0.79 and 0.60 mmHg*min/% after one and 
three months respectively and remained stable during longer follow-up. CMP 
in the thrombosed leg was lower than in the healthy leg during the entire 
follow-up period (p<0.05). CMP improved after three months from 61% to 67% 
after six months and 72% after two years, but declined after six years to 66%. 
The decline of the thrombosis score was similar to the VOR (resp. 4.4 after 
diagnosis, 2.6 after one month, 1.6 after three months to 1.5 after two and six 
years). Reflux was present in 2.9 segments after three months and increased 
slightly to 3.1 after one and two years.
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2
One month after diagnosis, VOR showed a higher AUC for PTS after one year 
than TS (0.70 and 0.57 respectively) (Table 2). The combination of VOR and TS 
did not improve the AUC (0.68). Of the examinations performed three months 
after diagnosis, TS and reflux as a single test showed the best AUC for PTS 
after one year, 0.70 and 0.69, respectively (Figure 2). The AUC increased with
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F igure  2 Receiver operating characteristic curves of the non-invasive venous 
tests as a single test for PTS after 1 year, 2 and 6 years.
VOR TS
Reflux CMP
1 - Specificity 1 - Specificity
-1 year 2 years 6 years
VOR = venous outflow resistance, TS = thrombosis score, CMP = calf muscle pump function.
the combination of TS and reflux to 0.75. Subsequent addition of VOR resulted 
in a minor improvement to an AUC of 0.77 (Figure 3). After exclusion of patients 
with ipsilateral recurrent DVT or distal DVT the AUC's of VOR, TS and reflux 
after three months for PTS after one year were 0.75 and 0.76, respectively.
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The AUC's of CMP as a single test or in combination with other tests was low. 
Measurement of TS of the popliteal and femoral vein only showed a similar 
AUC (0.71) for TS but not for reflux (0.61). AUC showed no or minimal decrease 
for PTS after two and six years.
F igure  3 Receiver operating characteristic curves of the non-invasive venous 
tests measured at three months as a combination of tests for PTS 
after 1 year.
A VOR and T S B VOR and R eflux
C T S  and reflux D TS, reflux and VOR
1 - Specificity 1 - Specificity
A. Venous outflow resistance and thrombosis score (VOR and TS), B. VOR and reflux, 
C. thrombosis score (TS) and reflux and D. the combination of TS, reflux and VOR.
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Discussion
This study shows that the incidence of PTS after DVT did not increase 
significantly after one year, but there was progression of severity of PTS 
symptoms. Furthermore, the combination of several venous examinations 
performed in the first three months after DVT can predict the development of 
PTS after one year with reasonable accuracy. The predictive value is less 
using a single venous test.
Regarding the incidence of PTS, this study is consistent with earlier studies 
that PTS can already be diagnosed in the first two years after acute DVT and 
that the incidence after two years does not increase significantly617. In addition, 
PTS was diagnosed in most of the patients with PTS as early as after the first 
year (88%) and progressed during longer follow-up resulting in a higher 
percentage of patients with the CEAP-classification 4, especially in patients 
with ipsilateral recurrent DVT. As ipsilateral recurrent DVT is a risk factor for 
PTS18, PTS class 4 was diagnosed more often after 6 years in patients with 
ipsilateral recurrent DVT in this study also. The absence of ulceration in this 
study could be related to the use of elastic stockings in many patients with 
PTS. A similar observation was done in a prospective study where all patients 
using regular compression therapy had no or only mild PTS after 12 years19. 
Despite the use of stockings during the first year the incidence of PTS 
diagnosed in this study is high. Comparison however is difficult because of the 
different classifications and definitions of PTS used in the studies. The CEAP- 
classification used in this study has been widely used since the introduction 
by the American Venous Forum in 1995 and it was found valuable and 
practical20.
The present study also demonstrates that even three months after diagnosis 
of DVT the combination of TS, reflux and VOR was able to identify patients at 
risk for PTS after 1 year with reasonable accuracy. So far in previous studies 
the extent of thrombus on initial presentation or initial signs were not related to 
ultimate clinical outcome2122 and risk factors or determinants of PTS were 
assessed only at final follow-up when symptoms had already appeared7. In 
accordance to our study, it was recently found that lack of recanalization 
combined with incompetence of the popliteal valve within the first six months 
after DVT increases the risk of PTS (RR 1.69)23. Reflux alone was not a predictor, 
but it was measured only in the popliteal vein. In the present study, reflux was 
measured in 10 vein segments and had a moderate predictive value. AUC 
improved in combination with TS, however the hemodynamic significance of
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the residual thrombus can not be determined with duplex but with VOR. This 
could be the explanation that addition of VOR to measurement of TS and reflux 
resulted in the highest AUC, i.e. predictive value. CMP in the early course after 
DVT has little or no predictive value both as single test as in combination with 
other tests. In contrast, it was shown that after longer follow-up diminished 
CMP is associated with progressive severity of PTS9 24.
The decrease of predictive value with longer follow-up can be explained by 
interference of other factors that have an influence on the final long-term 
outcome, such as non-compliance of wearing the elastic stocking, intercurrent 
illnesses, recurrent DVT and incomplete follow-up. In a randomized trial 
studying the effect of compression stockings final follow-up was completed in 
90%6, however, in other similar long term follow-up studies the percentage of 
patients suitable for final analysis was much lower varying between 35% to 
77%717-19 21 25. Shortening of follow-up in studies concerning the PTS to a 
maximum of two years or even one year would therefore result in a higher 
percentage of complete follow-up, less costs and increase of efficiency. 
Further improvement could be achieved by using the measurement of TS, VOR 
and reflux at three months follow-up as a proxy or surrogate endpoint for 
PTS.
Both VOR and duplex are non-invasive tests with a good interobserver 
variability1316 and can easily be used in studies and usual patient care. Apart 
from scientific reasons these methods could also be useful in clinical practice. 
The possibility of identification of patients at risk for PTS in the first three 
months after DVT could have several advantages such as more intensive 
treatment of these patients or programs to improve the compliance for elastic 
stockings in patients at risk.
This study has several limitations. Firstly, in accordance with comparable 
studies in DVT-patients, follow-up was not complete in half of the patients 
because of mortality, drop-out from the study or withdrawal of consent. As 
these patients were slightly older, this could result in an underestimation of the 
incidence of PTS at longer follow-up. However, of the patients who completed 
the six year follow-up period only 2 patients progressed to PTS after two years. 
Secondly, ipsilateral recurrent DVT was diagnosed in 11 patients and the 
incidence of PTS was higher in these patients. Exclusion of these patients, 
however, resulted in minimal changes of AUCs. Residual thrombus not only 
increases the risk of recurrent DVT but, without recurrent DVT, also of PTS23. 
At last, duration of anticoagulation was longer than three months in about half
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the patients. Data about the importance of the influence of duration of antico­
agulation in respect to PTS though are lacking. In contrast to an earlier study 
on DVT-resolution there were no differences in INR-levels between patients 
with or without PTS26, possibly because mean INR-levels were above 2.0 in 
both patient groups.
In conclusion, in this study the incidence of PTS after DVT did not increase 
significantly after one year, whereas during longer follow-up the severity of 
PTS rose in patients with PTS. Secondly, measurement of TS, reflux and VOR 
three months after DVT could predict with reasonable accuracy the risk of PTS 
after one year of follow-up. To improve efficiency of studies on PTS measurement 
of these parameters after three months could be used as a surrogate endpoint 
or proxy for PTS. Moreover, this study supports the concept that the follow-up 
time in these studies for final endpoints can be reduced to one or two years.
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Abstract
O bjective
Deep vein thrombosis (DVT) is a multifactorial disease. Recently, inflammation 
has been suggested as a risk factor for DVT. The question is whether 
inflammation is a cause of venous thrombosis or rather a result of the 
thrombotic process.
M ethods
We studied the inflammatory response in the acute phase of DVT with inleukin-6 
(IL-6), interleukin-8 (IL-8) and C-reactive protein (CRP) as inflammatory 
markers. Plasma concentrations were measured on the day of admission (day 
0) in 40 patients with acute DVT confirmed by phlebography and in 33 patients 
with clinical suspicion of DVT but negative phlebography results (controls). In 
patients with DVT inflammatory markers were also examined on five subsequent 
days.
R esu lts
On day 0, the median concentrations in plasma of IL-6, IL-8 and CRP were 15.0 
pg/mL (range <3 to 70), 7.0 pg/mL (range <3 to 76), 37.5 mg/L (range 7 to 
164), respectively, in the patient group and less than 3 pg/mL (range <3 to 11; 
P<0.001), 6.0 pg/mL (range <3 to 52; P=0.08) and 5.0 pg/ml (range <7 to 66; 
P<0.001), respectively, in the controls. During the next days, IL-6 showed a 
gradual decline in patients with DVT from 15.0 to 5.5 pg/mL (P<0.001), IL-8 
concentration was relatively constant in time and CRP concentration declined 
from 37.5 to 21.5 mg/L (P=0.01).
C onclus ion
Our data show an apparent inflammatory response with highest measured 
concentrations of inflammatory markers on the day of admission and a 
subsequent decrease during the next days. This response supports the 
hypothesis that elevated inflammatory markers are a result rather than a cause 
of venous thrombosis.
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Introduction
Deep vein thrombosis (DVT) occurs with an incidence rate of 1 to 2 per 1000. 
Known risk factors are deficiencies of protein C, protein S, antithrombin III, 
factor V Leiden and a mutation of prothrombin (Factor II), immobilization, 
surgery, trauma, pregnancy, malignant disease, use of oral contraceptives, 
hyperhomocysteinemia and elevated concentrations of factor VIII1-3. In last 
years several new risk factors have been detected like factor IX,4 factor XI5 and 
thrombin activatable fibrinolysis inhibitor6.
Chronic systemic inflammation is a risk factor for atherosclerosis, and it has 
been shown that markers of low-grade systemic inflammation are associated 
with a future risk of coronary heart disease7. The relationship between 
inflammation and venous thrombosis remains less well studied. An increase of 
the inflammatory markers interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte 
chemotactic protein was found in patients with recurrent DVT8, and elevated 
IL-8 plasma concentrations were measured in patients after a first thrombotic 
event9. Because these markers were measured at least 6 months after the 
thrombotic event, it was unlikely that the thrombosis itself was responsible for 
the increased plasma levels. Therefore, it was suggested that inflammation 
was a risk factor for DVT. In the latter study, the concentration of another 
inflammatory parameter, C-reactive protein (CRP), was also increased in 
patients with thrombosis10. However, in a prospective study, higher base-line 
CRP concentration was associated with a higher risk of future myocardial 
infarction and stroke but not with DVT11. In contrast to the suggestion that low 
grade inflammation is a risk factor, it can also be hypothesized that acute DVT 
causes an inflammatory response, which may persist for a longer period.
To test this hypothesis, we studied the question of whether an immediate 
systemic inflammatory response occurs in DVT. To answer this question we 
determined IL-6, IL-8, and CRP as inflammatory markers in patients with DVT, 
both at diagnosis and during the follow-up period and compared these with 
control subjects on the day of presentation. Furthermore, we analyzed the 
diagnostic value of the inflammatory markers on the day of admission.
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Methods
Patients
The study population consisted of patients who participated in a previous 
study that dealt with the exclusion of DVT with D-dimer testing12. In short, 112 
consecutive outpatients were referred to the emergency department because 
of clinical suspicion of DVT. Patients were excluded with one or more of the 
following criteria: treatment with anticoagulant therapy (n = 1), recent surgery 
less than 8 days previously (n = 0), refusal or inability to give informed consent 
(n=5), and inability to perform ascending contrast venography or inadequate 
results of the venographic examination (n=7). Ninety-nine patients were 
included and evaluated with ascending contrast venography for the diagnosis 
of DVT, defined as a persistent intraluminal filling defect in at least two 
projections. When DVT was diagnosed, patients were admitted to the hospital 
and treated with intravenous heparin therapy for a minimum of 5 days. Warfarin 
therapy was started concurrently for three months. When DVT was excluded, 
the patients were discharged and no further follow-up was performed (these 
patients are further named control-subjects). The study was restricted to 
patients with a complete set of sera for the day of admission and the 5 
subsequent days, because in some patients, after measurement of D-dimers, 
no sera remained.
The study protocol was approved by the Institutional Review Board of the Sint 
Joseph Hospital Veldhoven, and informed consent was obtained from all the 
study participants.
B lood  co lle c tion
Blood was collected within 2 hours of presentation in the emergency 
department and before administration of heparin therapy if DVT was diagnosed. 
After a positive diagnosis of DVT and admission to the hospital, blood was 
drawn daily between 8.00 and 10.00 AM for the next 5 days. Blood was 
collected into 4.5 mL siliconized glass vacutainer tubes that contained 0.45 
mL of 0.109 mol/L sodium citrate. Platelet poor plasma was prepared by 
centrifugation at 3000g for 15 minutes at 20°C, mixed, aliquoted, frozen, and 
stored at -80°C until analysis. At the time of the assay, the samples were 
thawed in a waterbath at 37°C for 10 minutes and after mixing allowed to stand 
at room temperature for at least 15 minutes before use.
A n a lys is  o f p lasm a co nce n tra tion s  o f IL-6, IL-8, CRP and D -d im er
IL-6 and IL-8 were determined by a commercially available enzyme-linked
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immunosorbent assay (Central Laboratory of the Netherlands Red Cross 
Blood Transfusion Service, Amsterdam, the Netherlands). These enzyme-linked 
immunosorbent assay kits are calibrated according to the standards of the 
National Institute for Biological Standards and Control (Potters Bar, United 
Kingdom). The detection limit is 3.0 pg/mL for both IL-6 and IL-8. CRP was 
assayed by an immuno-assay on a Vitros 250 (Ortho Clinical Diagnostics, 
Rochester, New York, USA), with a detection limit of 7 |ig/ml.
In the previous study, 13 D-dimer methods were tested12. The Tinaquant 
D-dimer assay (Roche Diagnostics, Mannheim, Germany) was one of the two 
assays with the highest sensitivity, so the results of the Tinaquant assay were 
used for this study.
S ta tis tica l ana lys is
The significance of differences in concentrations between the patients and the 
control subjects was tested with the Mann-Whitney test. P-values of less than 
0.05 were considered significant. Furthermore, we compared the presence of 
elevated plasma concentrations in control subjects and patients with DVT 
using the x2- test. Elevated levels of IL-6, IL-8 and CRP were defined as 
concentrations of more than the 90th percentile of the distribution in the 
control subjects. The significance of the difference in concentration during the 
time course was evaluated with the Mann-Whitney test for paired samples. 
The correlation coefficient was used for the assessment of the relation between 
inflammatory parameters and D-dimer levels. The correlation was defined as 
good if more than 0.75, moderate if between 0.50 to 0.75 and poor if less than 
0.50. With the Pearson correlation test the significance of the correlation 
coefficient was calculated and defined significant at the 0.01 level (two-tailed). 
The diagnostic values of the inflammatory parameters were evaluated 
by receiver operating curves (ROC), which were constructed for IL-6, IL-8, 
CRP and D-dimer by plotting sensitivity (true positive fraction) towards one- 
specificity (false positive fraction). Areas under the curves (AUCs) were derived 
from these curves as an estimate of the overall diagnostic performance.
Results
In 50 of the 99 included patients, the clinical suspicion of DVT was confirmed 
with venography. In the remaining 49 patients, the diagnosis was excluded. 
Plasma was available in 40 of the patients with DVT (17 male and 23 female) 
and in 33 control subjects (12 male and 21 female). In the other patients, after
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measurement of D-dimers not enough sera remained for all days. There were 
no differences in clinical characteristics of patients included in this study when 
compared with all the patients. The median age of the patients with DVT was 
55.7 years (range 27 to 87 years) and of the control subjects 52.0 years (range 
23 to 79 years). The median duration of symptoms was 8 days (range 1 to 42 
days). Five patients (7%) had symptoms for longer than 10 days. The following 
risk factors for DVT were present in 18 patients: malignant disease (n=5), 
immobilization (n=5), recent trauma (n=3), oral contraceptive use (n=2) and 
previous operation (n=3, <8 days were excluded). Of the DVT group four 
patients had distal thrombosis and 36 had proximal thrombosis.
At the day of admission, the median plasma concentrations of IL-6, IL-8 and 
CRP were higher in the patients with DVT as compared with the control 
subjects (Fig. 1). In the patients with DVT the median plasma levels of IL-6, 
IL-8, and CRP were 15.0 pg/mL (range <3 to 70 pg/mL), 7.0 pg/mL (range <3 
to 76 pg/mL ) and 37.5 mg/L (range <7 to 164 pg/mL), respectively, and in the 
control subjects were less than 3 pg/mL (range <3 to 11 pg/mL; P<0.001), 6.0 
pg/mL (range <3 to 52 pg/mL; P = 0.08) and 5.0 pg/mL (range <7 to 66 pg/mL; 
P<0.001). The 90th percentile of control subjects was respectively 7.6 pg/mL, 
9.8 pg/mL and 36.2 mg/L. In patients with DVT elevated plasma levels of IL-6 
were found in 64%, of IL-8 in 39%, and of CRP in 51% as compared with 10% 
in the control group (p<0.01). Although the number of patients with distal 
thrombosis was small (n = 4), these patients had considerably lower levels of 
inflammatory markers (median plasma levels: IL-6 <3 pg/mL, IL-8 5.5 pg/mL, 
and CRP 6.0 mg/L) than did patients with proximal DVT (median plasma levels: 
IL-6 19.4 pg/mL, IL-8 11.3 mg/mL, and CRP 53.2 mg/L). There were no 
differences in inflammatory markers between patients with known risk 
factors, like malignant disease or recent trauma and patients with idiopathic 
thrombosis.
During the follow-up period levels of IL-6 declined to 5.5 pg/mL after five days 
of treatment (Fig. 2). Median levels of IL-8 did not change over time. The 
median CRP showed an initial rise on the 2nd and 3rd day from 37.5 mg/L to
50.0 and 51.0 mg/L and then declined to 21.5 mg/l. Despite the decline in IL-6 
and CRP levels, the concentrations after 5 days were still increased as 
compared with the controls at the day of presentation (IL-6 5.5 pg/mL versus 
< 3.0 pg/ml; P=0.003; and CRP, 21.5 mg/L versus 5.0 mg/l; P=0.001). At day 
5 elevated levels (>90th percentile of controls) of IL-6, IL-8, and CRP were still 
found in 35%, 41%, and 39%, respectively, of patients with DVT (all P<0.01).
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F i g u r e  1 Plasma levels in control-subjects and patients with DVT of IL-6, 
IL-8 and CRP.
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Figure 2 The median levels of inflammatory parameters in patients with DVT 
on day of admission (day 0) and during five subsequent days.
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Fig. 2a: IL-6, fig. 2b: IL-8 and fig. 2c: CRP. The dotted lines represent the 90th percentile of the 
distribution of control-subjects on day of presentation.
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Figure 3 ROC curve analysis of the accuracy of IL-6 (3a), IL-8 (3b), CRP (3c) and D-dimer levels (3d) at the day of presentation 
for the diagnosis of DVT.
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CRP: r=0.72; n=62; p<0.01). The receiver operating curves for IL-6, IL-8, CRP 
and D-dimer levels are shown in Fig. 3. AUCs of the inflammatory parameters 
were 0.91, 0.63, and 0.88, respectively, as compared with the AUCs of D-dimers 
(0.96).
Discussion
This study shows an apparent systemic inflammatory response with elevated 
plasma levels of IL-6, IL-8, and CRP in patients with DVT. IL-6 and CRP showed 
a gradual decline during treatment, whereas IL-8 remained elevated in time. 
These results support the hypothesis that inflammation is a result of the 
thrombotic process rather than a cause of DVT.
It has been suggested that low-grade inflammation is a cause of DVT because 
elevated IL-6, IL-8 and monocyte chemotactic protein-1 concentrations were 
found in patients after a thrombotic event89. We cannot exclude that higher 
levels of inflammatory markers can be present because of risk factors in some 
of the patients with DVT (like malignant disease or recent trauma). However, 
there was no difference in markers between patients with idiopathic thrombosis 
or patients with a risk factor. It could be expected that, in case of persistent 
systemic inflammation as a cause of DVT, concentrations of inflammatory 
markers are steady instead of declining. Although this alternative hypothesis 
of low-grade persistent inflammation as a cause of DVT is not finally excluded, 
the course of the inflammatory markers is in our opinion strongly suggestive 
for the hypothesis that DVT is followed by an inflammatory response.
Except for elevated CRP-levels at diagnosis of DVT1314, no other studies have 
been published on inflammatory markers in the acute phase of DVT in humans. 
In an experimental baboon model of DVT, IL-6 and IL-8 concentrations peaked 
on day 2 after stasis-induced DVT. Unlike other cytokines, only IL-6 showed a 
significant relation with the extent of thrombosis on fibrinogen scanning. DVT 
was associated with a venous wall inflammatory response that consisted of an 
early neutrophil infiltration into the vein wall, followed by extravasation of 
monocytes, macrophages, and lymphocytes15. The inflammatory response in 
the vein wall could be visualized by gadolinium-enhanced magnetic resonance 
venography that showed enhancement around the thrombosed veins, which 
diminished in approximately 2 weeks16. In our study, during treatment in the 
subsequent days after the diagnosis of DVT, IL-6 and CRP levels declined and 
IL-8 level was relatively constant. CRP concentrations peaked during two days,
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similar to another study in DVT13. Because the inflammatory response is 
initiated and propagated by further thrombosis15, the decline of markers is most 
probably the effect of treatment with anticoagulants. Although anti-inflammatory 
agents may prevent DVT17 and heparin possesses anti-inflammatory properties 
distinct from its anticoagulant properties and inhibited vein wall neutrophils 
in an animal thrombosis model, the mechanism is unknown and the anti­
inflammatory effects may not be cytokine-m ediated18. For this reason, we 
think that the course of the inflammatory markers is not caused by the anti­
inflammatory effects of the treatment with heparin but is the result of decrease 
of the thrombotic process.
The control subjects in this study were patients with a clinical suspicion of DVT 
with negative phlebography results. Because the main priority was exclusion 
of DVT, an alternative diagnosis was not always clear and the control subjects 
were referred to their general practitioner. The differential diagnosis of DVT 
includes, for example, lymphedema, muscle trauma, hemorrhage, arthritis, 
tendonitis, and erysipelas. Some of these disorders may also cause elevations 
of inflammatory parameters. Although in most patients no substantial elevation 
of inflammatory parameters was found, it can be expected that in comparison 
with healthy controls the inflammatory response in DVT is even more apparent.
Several earlier studies showed elevated CRP levels at diagnosis of DVT. 
Although CRP concentration was not a reliable marker for exclusion of DVT, 
the sensitivity of an elevated CRP level at time of diagnosis was 72 to 100%1314. 
As in our study, lower CRP levels were found in patients with distal thrombosis13. 
When elevation of inflammatory markers are supposed to be the result of the 
DVT, they might also be used as diagnostic markers for DVT. Therefore, we 
looked at the diagnostic value of these markers compared with D-dimer. 
Although in our study, D-dimer levels showed the highest sensitivity and 
specificity, the AUCs of IL-6 and CRP compared with D-dimer can also be 
considered as good. The correlation of IL-6, IL-8, and CRP levels with D-dimer 
levels at diagnosis was only moderate. Although it has been suggested that 
initial D-dimer levels may be related to the extent of the thrombosis, this 
correlation is relatively weak. This may be because of differences in fibrinolytic 
activity between individuals19. It appears that the processes of fibrinolysis and 
inflammation may interact in DVT, but the extent of the inflammatory process 
cannot be estimated with determination of D-Dimer levels.
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In conclusion, in the acute phase of DVT, we found an apparent systemic 
inflammatory response with highest measured concentrations of inflammatory 
markers on day of admission and a subsequent decrease during the next 
days. This supports the hypothesis that elevated cytokines in patients with 
DVT are more likely to be a result of the thrombotic process rather than a 
cause of DVT.
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Abstract
O bjective
The aim of this study was to investigate whether inflammatory markers 
interleukin-6 (IL-6) and C-reactive protein (CRP) in the acute phase of deep 
vein thrombosis (DVT) are associated with elevated venous outflow resistance 
(VOR), thrombosis score (TS), reflux and the development of clinical post- 
thrombotic syndrome (PTS).
M ethods
In 110 patients with a first DVT, plasma concentrations of IL-6 and CRP were 
determined on the day of admission. VOR, TS and reflux were measured 7 
days, 1 and 3 months after diagnosis. After 1 year patients were evaluated for 
PTS using the Clinical, Etiologic, Anatomic and Pathophysiologic (CEAP) 
classification and Villalta-scale.
R esu lts
Median levels of IL-6 and CRP were 7 pg/ml and 21 mg/l, respectively. After 3 
months, VOR was elevated in 33 patients (30%), TS in 33 (30%) and reflux in 
57 (52%). Incidence of PTS was 36.7 % using CEAP > 3 and 34.5% using 
Villalta-scale > 5. Elevated levels of IL-6 and CRP were related to higher 
outcomes of VOR after 3 months (relative risks (RR) 2.4 (95% CI 1.5-3.9) and 
1.4 (1.1-3.3), respectively) and for IL-6 to TS (1.5 (1.1-2.1)). For reflux no relation 
was found. After 90 days, elevated outcomes of VOR, TS and reflux were 
related to PTS after 1 year. The association of IL-6 and CRP with PTS was 
weak using the CEAP classification with a RR of 1.2 (0.7-2.2) and 1.8 (0.9-3.3) 
and absent according to the Villalta-scale 0.6 (0.2-1.4) and 1.2 (0.6-2.5), 
respectively.
C onclus ion
The results of this study suggest that inflammation might play a role in incomplete 
thrombus clearance, venous outflow obstruction and the development of PTS 
after 1 year.
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Introduction
The post-thrombotic syndrome (PTS) is a chronic and frequent complication 
of deep vein thrombosis (DVT). Symptoms are persistent or intermittent pain, 
heaviness, swelling, itching, tingling or cramping and are typically aggravated 
by standing or walking and tend to improve with rest and recumbency. Typical 
clinical signs of PTS include edema, venous ectasia, hyperpigmentation, 
eczema, varicose collateral veins and, in severe cases, lipodermatosclerosin 
and venous ulceration1. Despite the use of elastic stockings, PTS occurs in up 
to 20-50% of patients with DVT, impairs the quality of life2, and has a substantial 
impact on health care costs3,4.
The clinical manifestations of PTS are probably a result of venous hypertension, 
which occurs as a consequence of venous valvular incompetence, persistent 
deep vein outflow obstruction, or both. In a previous study, we have shown 
that during the follow-up of DVT the occurrence of PTS after 1 year was best 
predicted by an increased venous outflow resistance (VOR), residual thrombus 
(measured as thrombosis score (TS)) and presence of reflux at 3 months5.
The destruction of venous valves and persistent outflow obstruction might be 
caused by the volume effect of the thrombus, but also by an inflammatory 
process which accompanies thrombosis. Studies in animals showed that 
inflammation in DVT involves both the venous vascular wall and the perivascular 
area67. In patients with DVT, we have demonstrated previously that inflammatory 
markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) are elevated 
as a result rather than a cause of venous thrombosis8. To our knowledge, no 
data exist examining the role of inflammation in the pathophysiology of PTS.
The aim of this study was to investigate whether increased levels of the 
inflammatory markers IL-6 and CRP in the acute phase of DVT are associated 
with elevated VOR, higher TS, reflux and with the subsequent development of 
clinical PTS.
Methods
Patien ts  and s tu d y  design
Between 2002 and 2005 consecutive outpatients with symptomatic DVT, 
confirmed by compression ultrasound, were considered for inclusion in the 
Post Thrombosis Study. Both patients with proximal thrombosis, involving the
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popliteal vein or above, and patients with distal thrombosis limited to the calf 
were included. Exclusion criteria were previous DVT, active malignancy, life 
expectancy less than 2 years, underlying infection, arterial insufficiency 
(Fontaine > 2b), use of anti-inflammatory medication, previous venous 
insufficiency, surgery, trauma or pregnancy in the 4 weeks prior to the DVT 
and the use of low-molecular weight heparin (LMWH) or oral anticoagulation 
before blood sampling. The study was approved by the local ethics committee 
and all patients gave informed consent.
All participants were treated with LMWH (dose based on body weight) and 
vitamin K antagonists (international normalized ratio (INR) 2-3) for at least 3 
months. They were instructed to wear sized-to-fit elastic stockings for at least 
two years. The stockings prescribed were class III (40 mmHg) thigh-length in 
case of proximal DVT for the first 3 months followed by knee-length stockings, 
or knee-length stockings only in case of distal DVT. For patients with arterial 
insufficiency or above 75 years of age, class II (30 mmHg) stockings were 
prescribed. Compliance was assessed by asking the patients. Almost all 
patients were treated in the outpatient clinic.
O utcom e m easures o f venous non-invas ive  exam ina tions
Follow-up visits and non-invasive examinations were planned after 7, 30 and 
90 days. VOR was measured in both extremities using strain-gauge plethys­
mography with the patient in a supine position with pneumatic cuffs around 
the thighs and strain-gauges around the calves910. After inflation of the cuffs 
the venous volume increases gradually. When venous pressure equals the 
effective congestive pressure and maximum volume was achieved, the 
cuff-pressure was released resulting in a volume decrease measured by 
plethysmography. At the point 0.5 s after pressure release, the tangent to 
volume record was drawn and the slope converted into a flow rate, which is the 
venous emptying rate (VER). This procedure is performed with five different 
cuff pressures. Subsequently, the corresponding VER values are plotted 
against the effective cuff pressures. The slope of the line through the point 
gives an angle p. Using analogy with Ohm’s law, the VOR is calculated as 1/ 
angle p. The VOR value is expressed in resistance units: mmHg*min/%. A VOR 
exceeding 0.8 mmHg*min/% was considered abnormal910. The non-thrombotic 
leg was used as a control.
Duplex examinations were performed by two experienced vascular technicians 
using a Toshiba SSA 270A scanner with a 3.75 or 5 MHz probe in low flow 
setting. The examination was performed with the patient in a reverse
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Trendelenburg position at 45 degrees, the knees flexed and the feet resting on 
a foot support. Sixteen vein segments were examined: the common femoral 
vein, the femoral vein (proximal and middle), the great saphenous vein 
(proximal, middle and distal), the popliteal vein, the short saphenous vein, the 
posterior and anterior tibial veins, the peroneal and gastrocnemial veins. 
In the calf, each artery is accompanied by two veins; these were numbered: 
one being the most superficial and two the deeper vein. The distal femoral 
vein is often not compressible because of the anatomical position in Hunter’s 
canal. After the third month, the peroneal, gastrocnemial and tibial anterior 
veins were only examined if thrombus was present at the initial examination, 
as these measurements were time-consuming and yielded little data. 
The results of the remaining 10 vein segments were used for analysis. 
The compressibility was assessed in the transverse plane with gentle pressure 
applied to the overlying skin using the duplex-probe. In the longitudinal plane, 
the presence of the Doppler signal is usually present; in the distal veins a flow 
signal was considered present after gently squeezing the extremity below the 
level of measurement. The definition of the thrombosis score (TS) was based on 
the description of extent of thrombus and site involvement by Porter11. A vein 
segment was considered occluded when the vein segment was non- 
compressible and no Doppler signal was found (TS=2) and non-occluded if it 
was not completely compressible but flow was still present (TS=1). A fully 
patent vein segment showed complete compressibility and flow (TS = 0). 
The TS values were calculated by counting the TS values of the 10 vein 
segments12,13.
Reflux was measured in the longitudinal plane and provoked in the proximal 
veins by the Valsalva maneuver and in the distal veins by manual compression 
with sudden release. Pathological reflux was defined as a reversed flow 
duration of more than 1 sec in the proximal veins and more than 0.5 sec in the 
distal veins91314.
D eterm ina tion  o f PTS
After 1 year, patients were evaluated by an experienced dermatologist who 
was unaware of the results of the venous examination. The severity of PTS was 
scored according to the clinical score (range 0-6) of the revised Clinical, 
Etiologic, Anatomic, and Pathophysiologic (CEAP) classification15 and the 
Villalta-scale16. In the CEAP-classification, patients with class 0 represent no 
visible or palpable signs of venous disease; class 1 telangiectasias, reticular 
veins or malleolar flare; class 2 varicose disease; class 3 edema without skin 
changes; class 4 skin changes ascribed to venous disease (pigmentation, 
lipodermatosclerosis); class 5 skin changes with healed ulcer and class 6 skin
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changes with active ulceration. PTS was defined as a CEAP-classification of
> 3 or more. The Villalta-scale, also called the Prandoni-scale, grades the 
severity from 0 to 3 of five symptoms (pain, cramps, heaviness, pruritus and 
paresthesia) and six signs (edema, skin induration, hyperpigmentation, venous 
ectasia, redness and pain during calf compression). A summed total score of
> 5 indicates PTS, and > 14 or presence of ulcer indicates severe PTS.
L a b o ra to ry  ana lys is
Blood was drawn at the time of diagnosis (before initiation of therapy), and on day 
7, 30 and 90. Blood was collected in siliconized glass vacutainer tubes that 
contained 10 mL of 0.18% ethylenediaminetetraacetic acid (EDTA) for determination 
of IL-6 and CRP. IL-6 concentrations were determined with a commercially 
available enzyme-linked immunosorbent assay (Central Laboratory of the 
Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands). 
These enzyme-linked immunosorbent assay (ELISA) kits are calibrated according 
to the standard of the National Institute for Biological Standards and Control 
(Potters Bar, United Kingdom). The detection limit of the assay is 3.0 pg/ml. CRP 
was assayed with an immunoassay on a Vitros 250 (Ortho Clinical Diagnostics, 
Rochester, NY), with a detection limit of 7 jug/ml.
S ta tis tica l ana lys is
The relationships between inflammatory markers, non-invasive vascular 
measurements and PTS are reported as relative risk ratio (RR), with the 
associated 95% confidence intervals (CIs) in brackets, using the Poisson 
regression model17-19. This model allows direct estimation of relative risks 
adjusted for age, gender, body mass index (BMI) and other co-variates. 
Because of the high incidence of PTS the use of this model is more appropriate 
than logistic models that only allow estimation of odds ratios.
Results
S tud y  p op u la tion
A diagnosis of DVT was established in 184 patients, of which 68 were excluded 
for the following reasons: malignancy (n=16), previous DVT (n=6), 
immobilization (n=5), recent surgery (n = 4), use of anti-inflammatory 
medication (n=3), severe underlying medical condition (n=3), recent trauma 
(n=2), pregnancy (n=2), bilateral thrombosis (n=1), age below 18 (n=1), 
already started with LMWH (n=1) and a combination of exclusion factors 
(n=24). Of the eligible 116 patients 3 patients refused participation and
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3 patients were lost to follow-up. Therefore, data of 110 patients were available 
for the final analysis. Among the participating patients, the risk factors for DVT 
were immobilization (n= 33), recent trauma (n= 12), oral contraceptive use 
(n= 23), surgery (between 4 weeks and 3 months prior) (n= 11) and positive 
family history (n= 36). The patient characteristics are shown in Table 1.
Table 1 Baseline characteristics of the patients (n=110).
Mean age at d iagnosis (range) 53.8 (25-86)
Male:female 59:51 (54:46%)
Location of DVT
Distal 13 (11.8%)
Proximal 97 (88.2%)
Left 63 (57%)
Right 47 (43%)
BMI (SD) 25.6 (4.9)
Duration of sym ptom s in days 6.8 (1-90)
IL-6 and CRP
The median IL-6 plasma concentration was 7 pg/ml on the day of diagnosis, 
and below detection limit at day 7, 30 and 90. The 80th percentile of baseline 
IL-6 concentration was 15 pg/ml. Among all patients the median plasma 
concentration of CRP was 20.5 mg/l on the day of diagnosis, 8 mg/l at day 7, 
and below detection limit after day 30 and 90. The 80th percentile of baseline 
CRP concentration was 54 mg/l.
VOR, TS and re flux
VOR was elevated (> 0.8 mmHg*min/%) in 65 (61%) patients on day 7, in 51 
(48%) patients on day 30 and in 33 (30%) patients on day 90. The median VOR 
declined in the first 3 months from 1.2 mmHg*min/% in the first few days after 
diagnosis to 0.8 and 0.6 mmHg*min/% after 1 and 3 months, respectively. 
Median TS scores declined from 5 (SD 3.4, range 0-13) on day 7 to 3 on day 30 
(SD 2.7, range 0-10) and to 1 (SD 2.3, range 0-10) on day 90. High TS > 3 were 
found in 65% of the patients on day 7, 50% on day 30 and 30% after 90 days. 
Reflux was present in 52% of the patients after 90 days. In 29% of the patients 
reflux was present in 1 or 2 vein segments, in 15% in 3 or 4 vein segments and 
in 9% in 5 or more vein segments.
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Inc idence  o f the  p o s t-th ro m b o tic  syndrom e
The patients were followed for over 1 year. Twelve patients experienced 
recurrent DVT, but only four recurrences occurred in the first year. After one 
year, the overall incidence of PTS was 36.7% according to the CEAP 
classification and 34.5% to the Villalta-scale. Mean Villalta score was 4.1 (SD 
3.8, range 0-19).
Compliance of stockings was good in both patients with and without PTS. 
The median numbers of days that stockings were worn during a week were 6.3 
(SD 1.6) for patients with PTS and 6,4 (SD 1.6, p=0.63) for patients without PTS.
R elative risks
On the day of diagnosis, increased levels of the inflammation markers IL-6 and 
CRP were related to higher outcomes of VOR after 3 months (IL-6: 2.4 (1.5-3.9) 
and CRP: 1.4 (1.1 -3.3)). IL-6 was also related to TS after 3 months (1.5 (1.1-2.1)). 
For reflux, no relation with levels of IL-6 and CRP was found (IL-6 1.0 (0.6-1.6) 
and CRP 1.1 (0.7-1.8)). All relative risks are shown in Table 2. Relative risks 
were not different when the group of patients with recurrent DVT was 
excluded.
After 1 year, 7 patients had complete obstruction of at least one vein segment. 
In these patients, levels of IL-6 and CRP were higher at the time of diagnosis 
than IL-6 levels in patients without complete obstruction. On day 1, mean 
levels of IL-6 for patients with and without complete obstruction were 16.2 (SD 
14.1) and 10.3 (SD 10.3), and mean levels of CRP were 51.1 (SD 37.0) and 29.4 
(SD 28.5) for these sets of patients. For days 7, 30 and 90, there were no 
differences in levels of inflammation markers. Thirty-eight patients had 
complete recanalization and no reflux after 1 year. Levels of IL-6 and CRP 
showed no differences compared to patients with vein abnormalities.
Elevated outcomes of VOR, TS and reflux after 90 days were related to a higher 
incidence of PTS after one year. Relative risks after 90 days were 2.1 (1.2-3.7),
2.0 (1.1-3.7) and 1.7 (1.0-2.2) for VOR, TS and reflux, respectively, according to 
the CEAP classification and 2.1 (1.2-3.8), 2.1 (1.1-4.1) and 1.7 (0.9-3.0) using 
the Villalta-scale (see Table 3).
The association of IL-6 and CRP with PTS was weak using the CEAP 
classification with RR of 1.2 (0.7-2.2) and 1.8 (0.9-3.3) and absent using the 
Villalta-scale 0.6 (0.2-1.4) and 1.2 (0.6-2.5), respectively (see Table 4). INR 
values of the patients were below 2.0 in only 9% of the time. Mean INR value 
was 2.84 (SD 0.32). Adjustment for INR did not change the results.
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Table 2 Relation between inflammatory parameters and non-invasive venous examinations.
Relation between tw o  variab les RR
unadjusted
95%CI RR
ad justed*
95%CI RR
adjusted
IL-6 > p80 VOR day 7 > 0.8 1.7 1.3-2.2 1.7 1.3-2.1 1.3
IL-6 > p80 VOR day 30 > 0.8 1.9 1.4-2.8 2.0 1.4-2.8 1.5
IL-6 > p80 VOR day 90 > 0.8 3.0 1.8-5.0 2.9 1.8-4.8 2.4
IL-6 > p80 TS day 7 1.2 1.1-1.3 1.2 1.1-1.3 1.1
IL-6 > p80 TS day 30 1.3 1.1-1.5 1.2 1.1-1.4 1.2
IL-6 > p80 TS day 90 1.5 1.1-2.0 1.5 1.1-2.0 1.5
IL-6 > p80 reflux day 90 1.0 0.6-1.6 1.0 0.7-1.6 1.0
CRP > p80 VOR day 7 > 0.8 1.4 1.1-1.9 1.6 1.2-2.2 1.3
CRP > p80 VOR day 30 > 0.8 1.4 0.9-2.0 1.5 1.0-2.3 1.1
CRP > p80 VOR day 90 > 0.8 1.7 1.0-3.0 2.1 1.2-3.9 1.4
CRP > p80 TS day 7 1.0 0.9-1.2 1.0 0.9-1.2 1.0
CRP > p80 TS day 30 1.0 0.8-1.3 1.0 0.8-1.3 1.0
CRP > p80 TS day 90 1.0 0.7-1.5 1.1 0.8-1.6 1.0
CRP > p80 reflux day 90 1.0 0.6-1.6 1.1 0.7-1.7 1.1
1.0-1.7
1.1-2.2 
1.5-3.9
1.0 - 1.3
1.0 - 1.5
1.1- 2.1 
0.6-1.6
1.0 - 1.9 
0.7-1.7 
0.8-2.4
0.8-1.2 
0.7-1.3 
0.7-1.4 
0.7-1.8
95%CI
* adjusted for age, sex and BMI
**  adjusted for age, sex, BMI and other soluble factors (IL-6, CRP, D-dimer) 
VOR = venous outflow resistance, TS= thrombosis score
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Table 3 Relation be tw een non-invasive venous exam inations and PTS afte r 1 year (C EA P -classifica tion > 3 and V illa lta  > 5).
Relation between two variables RR
unadjusted
95% C I RR
adjusted*
95% C I RR
adjusted**
95% C I
VOR day 7 > 0.8 PTS (CEAP > 3) 3.5 1.6-7.6 2.4 1.1-5.1 2.1 0 .9-5.1
VOR day 30 > 0.8 PTS (CEAP > 3) 2.7 1.5-4.9 2.1 1.3-3.6 2.2 1.2-4.0
VOR day 90 > 0.8 PTS (CEAP > 3) 2.6 1.6-4.2 1.9 1.2-3.1 2.1 1.2-3.7
TS day 7 PTS (CEAP > 3) 5.3 0 .8-35.9 2.9 0.5-17.0 2.5 0 .5-12.9
TS day 30 PTS (CEAP > 3) 3.0 1.0-8.8 2.4 0.9-6.5 2.0 0 .8-5.4
TS day 90 PTS (CEAP > 3) 2.2 1.1-4.1 1.8 1.0-3.1 2.0 1.1-3.7
Reflux PTS (CEAP > 3) 1.9 1.1-3.2 1.7 1.0-2.8 1.7 1.0-2.8
VOR day 7 > 0.8 PTS (Vi > 5) 2.3 1.2-4.5 2.3 1.2-4.5 3.6 1.7-7.5
VOR day 30 > 0.8 PTS (Vi > 5) 1.6 0 .9-2.7 1.5 0.9-2 .6 2.2 1.2-4.1
VOR day 90 > 0.8 PTS (Vi > 5) 1.7 1.0-2.8 1.6 0.9-2.7 2.1 1.2-3.8
TS day 7 PTS (Vi > 5) 4.9 0 .7-33.2 5.0 0.7-32.7 6.0 0 .9-41.1
TS day 30 PTS (Vi > 5) 2.9 1.0-8.6 2.8 1.0-8.4 3.4 1.1-10.1
TS day 90 PTS (Vi > 5) 1.5 0 .9-2 .8 1.5 0.8-2.8 2.1 1.1-4.1
Reflux PTS (Vi > 5) 1.7 1.0-3.0 1.6 0.9-2 .8 1.7 0 .9-3.0
* adjusted for age, sex and BMI
**  adjusted for age, sex, BMI and other soluble factors (IL-6, CRP, D-dimer)
VOR= venous outflow resistance; TS= thrombosis score; CEAP= Clinical, Etiologic, Anatomic and Pathophysiologic classification; 
V i= Villalta scale for PTS
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Table 4 Relation between inflammatory parameters and PTS after 1 year (CEAP-classification > 3 and Villalta > 5).
Relation between two variables RR
unadjusted
95% C I RR
adjusted*
95% C I RR
adjusted**
IL-6 > p80 PTS (CEAP > 3) 1.4 0.8-2.4 1.3 0.8-2.1 1.2
CRP > p80 PTS (CEAP > 3) 1.3 0.8-2.3 1.8 1.0-3.0 1.8
IL-6 > p80 PTS (Vi > 5) 0.6 0.2-1.3 0.5 0.2-1.2 0.6
CRP > p80 PTS (Vi > 5) 0.9 0 .5-1.8 0.9 0.5-1.8 1.2
* adjusted for age, sex and BMI
**  adjusted for age, sex, BMI and other soluble factors (IL-6, CRP, D-dimer)
cn
95% C I
0 .7-2.2 
0 .9-3.3
0 .2-1.4 
0.6-2.5
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Discussion
To our knowledge, this is the first prospective study in DVT patients to 
determine the relation between inflammation in the acute phase of DVT and 
PTS as long-term complication. We have demonstrated that in patients with 
DVT, elevated concentrations of IL-6 and CRP at baseline were associated 
with elevated VOR after 3 months and for I L-6 with high TS. No associations 
were found for reflux. Secondly, subjects with elevated VOR, TS and reflux 
three months after DVT had a higher risk of developing PTS after 1 year, which 
is in agreement with our previous study5. The association of I L-6 and CRP with 
PTS after one year was weak using the CEAP classification for PTS and absent 
according to the Villalta-scale. Although the relation between inflammation 
and PTS is not yet fully elucidated, the results of our study suggest that 
inflammation might play a role in incomplete thrombus clearance, venous 
outflow obstruction and the future development of PTS.
Based on previous results and the current study, it is likely that two processes 
are involved in the development of PTS: (i) persistent obstruction (measured 
as VOR) because of incomplete thrombus clearance and venous wall fibrosis 
as a result of the inflammatory response in both the thrombus and the vein 
wall; and (ii) reflux as a result of direct damage to the valves by the thrombus 
itself or by entrapment in the fibrotic process of the vein wall. Both obstruction 
and reflux result in venous hypertension and PTS (see Figure 1).
Interestingly, in our study, the detection of an association between inflammation 
and PTS as an endpoint depended on which clinical classification system was 
used. It is important to keep in mind that there is no gold standard or test to 
diagnose PTS. Although several classification systems have been developed 
and evaluated, their reliability, valid ity or responsiveness to change and 
their use for the routine clinical monitoring of DVT patients have not been 
fu lly assessed20. In a study in 124 patients with previous DVT, all PTS 
classifications showed a positive association with the reference standard 
ambulant venous pressure (AVP), but both the correlation of CEAP classification 
and the Villalta scale (also referred as Prandoni-scale) with AVP was moderate 
(0.22 and 0.27, respectively), and the correlation between the CEAP and 
Villalta-scale was 0.42 (0.29-0.56)21. Furthermore, AVP showed considerable 
overlap in the different clinical groups. The CEAP classification has been 
widely implemented and is based on objective symptoms only and can serve 
as the basis for initial evaluation of PTS, but is relatively static for skin changes 
in time. The Villalta scale also includes subjective signs, and has no specific
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Figure  1 Hypothetic development of PTS: DVT initiates an inflammatory 
response resulting in (incomplete) thrombus clearance (measured 
as TS), vein wall changes and fibrosis resulting in elevated VOR. 
Direct mechanical damage to the valves might cause reflux of the 
valves. Both persistent obstruction and reflux because of valvular 
insufficiency lead to venous hypertension and PTS.
criteria for grading of the individual elements of the score. So, with the absence 
of a gold standard test, measuring outcomes of PTS is complex. The relation 
between inflammation and PTS can also be influenced by other variables 
determining PTS, like intensity of anticoagulation22 and the use of compression 
stockings, as the use of compression stockings prevents the development of 
PTS4. In this study, the intensity of anticoagulation was good, and compliance 
with wearing the stockings was high in all patients. Taking into account the 
above considerations, we conclude that there is a weak association between 
inflammation and PTS.
Moreover, the hypothesis that the inflammatory response leads to vein wall 
changes is supported by animal studies. Resolution of DVT resembles wound 
healing with early influx of neutrophils and monocytes, thrombus neovascular­
ization, collagen deposition and late fibrosis leading to increased vein wall 
stiffness2324. Inhibition of inflammation decreased the vein wall injury and 
stiffness independent of thrombus size25. Patients with DVT might benefit from 
treatment with anti-inflammatory drugs or longer treatment with LMWH, as 
LMWHs possess anti-inflammatory properties distinct from its anticoagulant
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properties26, and LMWH improves vein wall re-endothelialization after DVT27. 
This hypothesis should be confirmed in future intervention studies.
A few issues about our study require comment. First, the number of patients 
excluded was high. The exclusion criteria were chosen to preclude the 
introduction of bias owing to detection of elevated levels of IL-6 and CRP as a 
result of other disorders than DVT and to ascertain that they represent the 
response to the thrombus. Secondly, 12 patients experienced recurrent DVT, 
the most important identified risk factor for PTS, but only four recurrences 
occurred in the first year. Exclusion of both these four patients as the total of 
12 patients with recurrent DVT, did not influence the results of the study.
In conclusion, although the relation between inflammation in DVT and PTS is 
not yet fully elucidated, the results of this study suggest that inflammation 
might play a role in incomplete thrombus clearance and vein wall changes 
resulting in PTS after 1 year. This suggests that a decrease in vein wall 
inflammatory response by anti-inflammatory medication or LMWH for a longer 
period of time may result in a decline in the manifestations of PTS.
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Abstract
O bjective
Several studies reported that obesity -  as reflected by the body mass index 
(BMI) - is associated with the development of the post-thrombotic syndrome 
(PTS). The pathophysiology of this relationship is unclear. Therefore, we 
investigated the relationship between BMI and venous function tests: the 
extent of thrombosis (expressed by the thrombosis score), venous reflux and 
the venous outflow resistance (VOR). Moreover, we did a meta-analysis on the 
effect of obesity and overweight on the incidence of PTS.
M ethods
In consecutive patients with a first DVT we assessed BMI and venous function 
tests at baseline and during follow-up. The occurrence of PTS was assessed 
after one year by a dermatologist on the base of the CEAP-classification and 
the Villalta-scale. We evaluated the relationship between BMI and the 
occurrence of PTS and the venous function tests. We also measured markers 
of inflammation (CRP and IL-6) that are known to be related to the development 
of PTS as well. Finally, we provide the results of a meta-analysis of published 
studies on the relation of BMI and PTS.
R esults
Out of 110 patients with DVT 37% developed PTS (CEAP > 3). In 18 patients 
with BMI > 30 the incidence of PTS was 12 (67%); in 45 patients with overweight 
the incidence was 17 (38%) and in normal weight patients the incidence was 
12 (26%). The mean VOR after 90 days was 1.0 (0.37-1.75) in obese patients 
compared to 0.53 (0.35-0.62) in normal weight patients (p for trend = 0.03). 
No relation was found with the extent of thrombosis or with reflux. In the 
meta-analysis of 8 studies (including the current study) a BMI > 30 was 
associated with an increased risk of PTS (RR=1.40 (95%CI 1.20-1.65)).
C onc lus ion
Our study and the meta-analysis show that patients with obesity have a higher 
risk of developing PTS after DVT. This might be explained by an increased 
venous outflow resistance. These observations emphasize the importance of 
prevention of overweight in general. Patients with obesity and DVT should be 
encouraged to a strict application of preventive measures (including wearing 
appropriate stockings).
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Introduction
After DVT many patients suffer from the post-thrombotic syndrome (PTS), 
which is associated with high morbidity and costs, and loss of quality of life1. 
Signs and symptoms include heaviness, pain, varices, edema, hyperpigmen­
tation and occasionally venous ulcers. Several studies reported an association 
between body mass index (BMI) and the development of PTS2-8, but the 
mechanism of this relationship is not clear. Therefore we studied the effect of 
obesity on PTS including the effect on different venous function tests. 
Furthermore, we investigated the relation between BMI and the development 
of PTS in a meta-analysis.
Methods
Patien ts  and s tu d y  design
Between 2002 and 2005 110 consecutive outpatients with symptomatic DVT, 
confirmed by compression echography, were included in the Post Thrombosis 
Study. Details of the study have been described elsewhere9. Exclusion criteria 
were previous DVT, active malignancy, life expectancy less than two years, 
underlying infection, arterial insufficiency (Fontaine > 2b), use of anti­
inflammatory medication, previous venous insufficiency, operation, trauma or 
pregnancy in the four weeks prior to the DVT, and the use of Low Molecular 
Weight Heparin (LMWH) or oral anticoagulation before blood sampling. The 
study was approved by the local ethics committee and all patients were asked 
for informed consent.
All participants were treated with LMWH (dose based on body weight) and 
vitamin K antagonists (INR 2-3) for at least three months. They were instructed 
to wear sized-to-fit elastic stockings for at least two years. The stockings 
prescribed were class III (40 mmHg) thigh-length in case of proximal DVT for 
the first three months followed by knee-length stockings, or knee-length 
stockings only in case of distal DVT. For patients with arterial insufficiency 
or above 75 years of age, class II (30 mmHg) stockings were prescribed. 
Most patients were treated in the outpatient clinic.
All patients were planned for follow-up visits after 7, 30 and 90 days for venous 
examinations and after 1 year for evaluation of PTS. At diagnosis and after one 
year BMI was obtained. Body weight was measured in light underwear by a 
precision scale to 0.5 kg and body height was measured by a precision meter
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to the nearest 0.01 m. BMI was calculated as body weight in kilograms divided 
by the square of the height in meters. A normal BMI was defined between 18.5 
kg/m2 to 24.9 kg/m2 , overweight between 25.0 and 29.9 kg/m2 and obesity is 
considered as a BMI of 30.0 kg/m2 or greater, according to the criteria of the 
World Health Organisation (1998)10.
D e fin ition  o f PTS
After one year, patients were evaluated by an experienced dermatologist who 
was unaware of the results of the venous examinations. The severity of PTS 
was scored according to the clinical score (range 0-6) of the revised CEAP 
classification (Clinical, Etiologic, Anatomic, and Pathophysiologic)11 and the 
Villalta scale12. In the CEAP classification patients with class 0 represent no 
visible or palpable signs of venous disease symptoms of PTS; class 1 
telangiectases, reticular veins or malleolar flare; class 2 varicose disease; 
class 3 edema without skin changes; class 4 skin changes ascribed to venous 
disease (pigmentation, lipodermatosclerosis); class 5 skin changes with 
healed ulcer and class 6 skin changes with active ulceration. PTS was defined 
as a CEAP-classification of > 3 or more. The Villalta scale grades the severity 
from 0 to 3 of five symptoms (pain, cramps, heaviness, pruritus and paresthesia) 
and six signs (edema, skin induration, hyperpigmentation, venous ectasia, 
redness and pain during calf compression). A summed total score of > 5 
indicates PTS, and > 14 or presence of ulcer indicates severe PTS.
M arkers o f in flam m ation
Blood was drawn at time of diagnosis (before initiation of therapy), and on day 
7, 30 and 90. Blood was collected in siliconized glass vacutainer tubes that 
contained 10 ml 0.18% EDTA for determination of interleukin-6 (IL-6) and 
C-reactive protein (CRP). IL-6 concentrations were determined with a 
commercially available enzyme-linked immunosorbent assay (Central 
Laboratory of the Netherlands Red Cross Blood Transfusion Service, 
Amsterdam, The Netherlands). These enzyme-linked immunosorbent assay 
(ELISA) kits are calibrated according to the standard of the National Institute 
for Biological Standards and Control (Potters Bar, United Kingdom). The 
detection limit of the assay is 3.0 pg/ml. CRP was assayed with an immunoassay 
on a Vitros 250 (Ortho Clinical Diagnostics, Rochester, NY), with a detection 
limit of 7 jug/ml.
M easurem ent o f venous fu n c tio n  tes ts
Duplex examinations were performed by two experienced vascular technicians 
using a Toshiba SSA 270A scanner with a 3.75 or 5 MHz probe in low flow
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setting. The examination was performed with the patient in a reverse 
Trendelenburg position at 45 degrees, the knees flexed and the feet resting on 
a foot support. 16 Vein segments were examined: the common femoral vein, 
the femoral vein (proximal and middle), the great saphenous vein (proximal, 
middle and distal), the popliteal vein, the short saphenous vein, the posterior 
and anterior tibial veins, the peroneal and gastrocnemial veins. In the calf each 
artery is accompanied by 2 veins; these were numbered: 1 being the most 
superficial and 2 the deeper vein. The distal femoral vein is often not 
compressible because of the anatomical position in Hunter’s canal. The results 
of the 10 vein segments were used for analysis. The compressibility was 
assessed in the transverse plane with gentle pressure applied to the overlying 
skin by the duplex-probe. In the longitudinal plane the presence of the Doppler 
signal is usually present; in the distal veins a flow signal was considered 
present after gentle squeezing the extremity below the level of measurement. 
The definition of the thrombosis score (TS) was based on the description of 
extent of thrombus and site involvement by Porter1314. A vein segment was 
considered occluded when the vein segment was non-compressible and no 
Doppler signal was found (TS=2) and non-occluded if it was not completely 
compressible but flow was still present (TS=1). A fully patent vein segment 
showed complete compressibility and flow (TS = 0). The TS values were 
calculated by counting the TS values of the 10 vein segments.
Reflux was measured in the longitudinal plane and provoked in the proximal 
veins by the Valsalva maneuver and in the distal veins by manual compression 
with sudden release. Pathological reflux was defined as a reversed flow 
duration of more than 1 sec in the proximal veins and more than 0.5 sec in the 
distal veins14.
Venous outflow resistance (VOR) was measured in both extremities using 
strain-gauge plethysmography with the patient in a supine position with 
pneumatic cuffs around the thighs and strain gauges around the calves15,16. 
After inflation of the cuffs the venous volume increases gradually. When 
venous pressure equals the effective congestive pressure and maximum 
volume was achieved, the cuff pressure was released resulting in a volume 
decrease measured by plethysmography. At the point 0.5 s after pressure 
release, the tangent to volume record was drawn and the slope converted into 
a flow rate, which is the venous emptying rate (VER). This procedure is 
performed with five different cuff pressures. Subsequently, the corresponding 
VER values are plotted against the effective cuff pressures. The slope of the 
line through the point gives an angle p. Using analogy with Ohm’s law, the VOR
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is calculated as 1/angle p. The VOR value is expressed in resistance units: 
mmHg*min/%. A VOR exceeding 0.8 mmHg*min/% was considered abnormal1516. 
The non-thrombotic leg was used as a control.
S ta tis tica l ana lys is
To assess the relationship between BMI and VOR we did a linear regression 
analysis and calculated mean VOR for patients with normal weight (< 25 kg/ 
m2), overweight (> 25-30 kg/m2) and obesity (> 30 kg/m2). To assess the 
relationship between BMI and PTS risk we calculated relative risks for patients 
with overweight and obesity compared to normal weight, using a Poisson 
regression model17. This model allows direct estimation of relative risks and 
adjustment for possible confounder. Because of the high incidence of PTS the 
use of this model is more appropriate than logistic models that only allow 
estimation of odds ratios. In a second model we calculated risk for patients 
with elevated VOR.
The assess the influence of BMI on inflammatory markers and venous function 
tests we calculated median levels with 95%CI for 3 categories of BMI (normal, 
overweight and obese).
A test for trend was performed with a generalized estimate equation model to 
take into account the intra-individual correlation between measurements on 
different time points.
M eta -ana lys is  o f s tud ies
Eligible studies were identified by searching the electronic literature (MEDLINE) 
for relevant reports published between 01-01-1990 and 01-01-2010 (using the 
term [(“post-thrombotic syndrome” OR “PTS”) AND (“BMI” OR “obesity”)], by 
hand searching reference list of original articles on this topic and by personal 
contact with relevant investigators in the field. Articles were retrieved if they 
were follow-up studies in patients with deep vein thrombosis with PTS as 
endpoint. To prevent duplication of data only the most recent and complete 
series reported by investigators were included in the analysis. Studies were 
assessed independently by two of the authors (MH and EK).
Data were collected on the frequency of BMI > 25 kg/m2 and BMI > 30 kg/m2 in 
patients with DVT who developed PTS and in those who did not develop PTS. 
When these frequencies were not retractable from the paper we derived them 
from the summary estimates (incidence of PTS, odds ratio’s and the distribution 
of BMI in the study). Because of the high incidence of PTS in most studies we 
used relative risks instead of odds ratio’s. Corresponding 95% confidence
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limits were estimated using W oolf’s method18. Summary estimates were 
obtained using a random effect model as implemented in the META-command 
in Stata 11.0. Heterogeneity was assessed using standard Chi-squared tests.
Results
Of the 110 patients enrolled in the study, median BMI at diagnosis was 25.6 kg/m2 
(range 15.8-45.7). Forty-seven patients (43%) had a normal or low BMI, whereas 
overweight was present in 45 patients (41%) and obesity in 18 patients (16%). 
Other baseline characteristics are summarized in Table 1.
The overall incidence of PTS after one year was 37% according to the CEAP- 
classification and 35% to the Villalta-scale. Four patients had recurrent DVT in 
the first year. Compliance of stockings was good in patients with and without 
PTS (mean numbers of days per week 6.5 SD 1.5) and INR-values of the 
patients were below 2.0 in only 9% of the time (mean INR 2.84 SD 0.32)). After 
one year BMI was increased slightly from 26.0 kg/m (SD 5.2) at baseline to 
26.6 (SD 6.0) after one year.
Table 2 shows the incidence of PTS in the three different BMI classes. Overweight 
was associated with a relative risk of 1.4 (95%CI 0.8-2.3) for PTS and obesity 
was associated with a relative risk of 2.3 (95% 1.4-4.0) using the CEAP-classifi- 
cation and 1.1 (95%CI 0.6-2.1) and 2.4 (95%CI 1.3-4.2) using the Villalta-scale.
Table 1 Baseline characteristics of the patients (n=110).
Mean age at d iagnosis (range) 53.8 (25-86)
Male:female 59:51 (54:46%)
Location of DVT
Distal 13 (11.8%)
Proximal 97 (88.2%)
Left 63 (57%)
Right 47 (43%)
BMI (SD) 25.6 (4.9)
Duration of sym ptom s in days 6.8 (1-90)
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Table 2 Relative risk for post-thrombotic syndrome (PTS) in overweight and 
obese patients with DVT.
BMI N PTS
(CEAP>3)
%
*cccc (95% CI)
< 25 47 12 26% 1 reference
25.0-29.9 45 17 38% 1.4 (0.8-2.3)
> 30 18 12 67% 2.3 (1.4-4.0)
BMI N PTS
(Villalta>5)
% RR* (95% CI)
< 25 47 13 28% 1 refe rence
25.0-29.9 45 13 29% 1.1 (0.6-2.1)
> 30 18 12 67% 2.4 (1.3-4.2)
* Adjusted for age and sex
F igure  1 The course of venous outflow resistance in lean, overweight and 
obese DVT patients.
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Table 3 shows the effects of the different BMI classes on markers of inflammation 
and the venous function tests. Both CRP levels and D-dimers were higher in 
obese and overweight patients. The relation with IL-6 was not clear, but this 
might be explained by a high number of measurements below the detection 
limit. No relation was seen for the thrombosis score and reflux. However, both 
the venous outflow resistance (VOR) of the throm botic leg and the non- 
thrombotic leg were higher in obese and overweight patients.
In Figure 1 the time-course of the VOR is given for the three BMI classes. 
The highest VOR is seen in the thrombotic leg of the obese patients. Although 
VOR diminished over time, it is still higher after one year in obese patients 
compared to those with normal BMI.
R esu lts  rev iew  and m eta -ana lys is
The MEDLINE search yielded 91 studies; 7 studies provided data on the 
relation between baseline BMI and the incidence of PTS2-8. Furthermore we used
F igure  2 The relative risk of the development of post-thrombotic syndrome 
after DVT for subjects with obesity (BMI > 30).
The size of the diamond is inversely proportional to the variance of the log odds ratio and the 
width of the diamond represents the 95% CI.
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Table 3a Inflammation and venous function in lean, overweight and obese patients with deep vein thrombosis.
BMI<25 25<BMI<30 BMI>30
Characteristic Day Median* LL UL Median* LL UL Median* LL UL
p for 
trend
Age (years) 54.0 45.5 60.0 53.0 45.9 63.3 65.0 40.0 71.0 0.02
Male (%) 49 34 64 63 46 78 44 16 71 0.78
D-dimer 1 2730 2319 4071 3490 2403 5129 4330 2163 8030 <0.01
IL-6 (pg/ml) 1 7.0 3.3 10.2 7.0 4.0 9.0 7.0 2.0 15.0 0.72
7 2.0 2.0 2.9 2.0 2.0 3.0 2.0 2.0 3.2
30 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 4.6
90 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 4.0
CRP (mg/l) 1 20.0 8.4 38.2 19.0 12.8 31.2 21.5 15.5 31.0 0.09
7 6.0 5.0 8.0 8.5 5.1 10.0 10.0 7.0 11.8
30 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 8.6
90 5.0 5.0 5.0 5.0 5.0 5.0 5.0 5.0 6.0
LL=lower limit 95% Cl, UL=upper limit 95%CI, ‘ except for male (%)
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Table 3b Venous function in lean, overweight and obese patients with deep vein thrombosis.
BMI<25 25<BMI<30 BMI>30
Characteristic Day Median* LL UL Median* LL UL Median* LL UL
p for 
trend
TS (score 0-20) 7 4.0 2.3 5.0 5.0 3.0 6.0 6.0 2.0 7.0 0.50
30 3.0 2.0 3.6 2.0 1.0 4.0 3.5 1.0 6.0
90 1.0 0.0 1.0 1.0 0.0 2.1 2.0 0.5 3.0
365 0.0 0.0 1.0 0.0 0.0 1.0 0.0 0.0 1.0
Reflux (%) 90 50 35 65 57 42 72 50 24 76 0.86
365 55 39 70 53 36 69 47 23 72
VOR (mmHg*min/%) 7 0.85 0.71 1.37 1.16 0.67 1.73 1.61 0.89 2.99 0.03
thrombotic leg 30 0.79 0.52 0.99 0.69 0.39 0.91 1.16 0.46 1.66
90 0.54 0.35 0.62 0.64 0.40 0.77 1.00 0.37 1.75
365 0.45 0.35 0.53 0.49 0.40 0.59 0.65 0.39 1.40
VOR (mmHg*min/%) 7 0.29 0.25 0.37 0.32 0.29 0.40 0.42 0.33 0.57 0.06
non-thrombotic leg 30 0.27 0.23 0.32 0.24 0.21 0.28 0.38 0.23 0.63
90 0.28 0.24 0.33 0.25 0.23 0.27 0.35 0.26 0.64
365 0.28 0.24 0.31 0.30 0.25 0.35 0.36 0.26 0.57
^  LL=lower limit 95% Cl, UL=upper limit 95%CI, TS= throm bosis score, VOR=venous outflow  resistance, *except for reflux
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Table 4 Studies on the relation between body mass index (BMI) and post-thrombotic syndrome (PTS).
Author Year Median
follow-up
(months)
N* %
female
%  prox 
DVT
PTS
definition
BMI
kg/m2 
cut off
Obese
PTS
Lean
PTS
Obese
NoPTS
Lean
NoPTS
Incidence 
PTS (%)
Biguzzi2 1998 47 51 100 100 CEAP > 1 22 15 17 4 15 63
McColl3 2000 51 40 100 ? CEAP > 1 26
30
13
4
16
25
5
2
6
9
73
Ageno4 2003 12 83 42 100 Villalta > 5 25
30
17
9
3
11
46
15
17
48
24
Stain5 2005 60 406 59 63 C E A P > 1 25 120 56 133 97 43
Kahn6 2005 26 141 44 100 Villalta > 5 cont OR 1.06 (0 .99- 1.13) 37
Dongen7 2005 58 244 57 100 Villalta > 5 cont OR 1.12 (1.04- 2.00) 33
Tick8 2008 10 1609 53 83 Villalta > 5 25
30
234
102
113
245
811
241
451
1021
25
Klappe current 12 110 46 88 C E A P >3 25
30
29
12
12
29
34
6
35
63
37
Villalta >5 25
30
25
12
13
26
38
6
24
56
35
N* number of patients w ith BMI available
CEAP=Clinical, Etiologic, Anatomic and Pathophysiologic classification of PTS; cont=  continuous.
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the data of the current study, see Table 4. The relative risk for BMI > 25 kg/m2 
was 1.22 (95%CI 1.09 -1.38) and for BMI > 30 kg/m2 1.40 (95%CI 1.20 -  1.65); see 
Figure 2. There was no significant heterogeneity between the studies at the 
25 kg/m2 level (x27= 6.3; p=0.51) nor at the 30 kg/m2 level (x27= 11.0; p=0.14).
Discussion
This study shows that BMI is a risk factor for PTS. This is consistent with other 
studies as shown in the results of the meta-analysis.
To explore a possible mechanism that can explain the relationship between 
obesity and PTS, we investigated the relationship between bodyweight and 
several venous function tests. We found no relationship with residual thrombus 
or reflux. This is in agreement with data from other studies. In a prospective 
cohort study of 98 patients with DVT there was no difference in the mean BMI 
and prevalence of obesity between patients who did and did not show 
thrombus regression after 6 and 12 months19. In a large multicentre trial, 862 
patients with DVT received different treatment regimens of either unfractionated 
heparin or LMWH. No relevant differences were observed between patients 
with thrombus regression or no regression in the demographic characteristics 
including BMI20. We did find a relationship with venous outflow resistance. 
This might indicate that increased bodyweight is associated with elevated 
venous outflow resistance resulting in increased venous pressure. Studies 
have demonstrated that increased intra-abdominal pressure is related to 
increased pressure in the femoral veins resulting in venous stasis and varicose 
veins in the lower limbs21-23. This concept is also supported by the fact that 
obese patients also had a higher VOR in the non-thrombotic leg.
Another explanation could be that there is more inflammation in obese patients 
that causes stiffening of the venous wall and subsequently an increased 
resistance. Two studies have demonstrated that inflammatory markers are 
related to the risk of PTS9,24. Furthermore, we found also higher levels of 
inflammatory markers and D-dimers in obese patients compared to normal 
weight patients. However, our study was too small to disentangle whether 
intraluminal pressure or inflammation is more important in the pathophysiology 
of PTS in obese DVT patients.
It seems very obvious to advice weight reduction to obese patients with DVT. 
This is highlighted by the fact that a significant proportion of patients treated
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for DVT experience weight gain after the acute event, likely because of reduced 
activity and of disease related symptoms. However, although weight loss is in 
general an important health issue, the most important implication of our study 
is to stress the importance of using preventive measures for PTS like wearing 
elastic stockings especially in patients with overweight and obesity.
In conclusion, patients with obesity have a higher risk of developing PTS after 
DVT. This might be explained by an increased venous outflow resistance. 
Patients with obesity and DVT should be encouraged to a strict application of 
preventive measures.
96
O BES ITY  AN D  THE D E VE LO P M E N T OF PTS
Reference List
1. Kahn SR. Frequency and determinants of the 11. 
postthrombotic syndrome after venous 
thromboembolism. Curr Opin Pulm Med 
2006;12:299-303.
2. Biguzzi E, Mozzi E, Alatri A, Taioli E, Moia M, 
Mannucci PM. The post-thrombotic syndrome 
in young women: retrospective evaluation of 
prognostic factors. Thromb Haemost 1998; 12. 
80:575-577.
3. McColl MD, Ellison J, Greer IA, Tait RC, 
Walker ID. Prevalence of the post-thrombotic 
syndrome in young women with previous 
venous thromboembolism. Br J Haematol 
2000;108:272-274. 13.
4. Ageno W, Piantanida E, Dentali F, Mera V, 
Squizzato A, Marchesi C, Steidl L, Venco A.
Body mass index is associated with the de­
velopment of the post-thrombotic syndrome. 14. 
Thromb Haemost 2003;89:305-309.
5. Stain M, Schonauer V, Minar E, Bialonczyk
C, Hirschl M, Weltermann A, Kyrle PA, Eich- 
inger S. The post-thrombotic syndrome: risk 
factors and impact on the course of throm- 15. 
botic disease. J Thromb Haemost 2005;3: 
2671-2676.
6. Kahn SR, Kearon C, Julian JA, Mackinnon B, 
Kovacs MJ, Wells P, Crowther MA, Anderson 
DR, Van Nguyen P, Demers C, Solymoss S,
Kassis J, Geerts W, Rodger M, Hambleton J, 
Ginsberg JS; Extended Low-intensity Anti- 16. 
coagulation for Thrombo-embolism (ELATE) 
Investigators. Predictors of the post-throm­
botic syndrome during long-term treatment
of proximal deep vein thrombosis. J Thromb 
Haemost 2005;3:718-723. 17
7. van Dongen CJ, Prandoni P, Frulla M, Mar- 
chiori A, Prins MH, Hutten BA. Relation be­
tween quality of anticoagulant treatment and 18. 
the development of the postthrombotic syn­
drome. J Thromb Haemost 2005;3:939-942.
8. Tick LW, Kramer MH, Rosendaal FR, Faber 19. 
WR, Doggen CJ. Risk factors for post-throm­
botic syndrome in patients with a first deep 
venous thrombosis. J Thromb Haemost 
2008;6:2075-2081.
9. Roumen-Klappe EM, Janssen MC, Van 20. 
Rossum J, Holewijn S, Van Bokhoven MM, 
Kaasjager K, Wollersheim H, Den Heijer M. 
Inflammation in deep vein thrombosis and
the development of post-thrombotic syn­
drome: a prospective study. J Thromb Hae­
most 2009;7:582-587. 21.
10. World Health Organization. Obesity - preventing 
and managing the global epidemic. WHO 
Consultation on Obesity Report, Geneva 1998. 22.
Eklof B, Rutherford RB, Bergan JJ, Carpen- 
tier PH, Gloviczki P, Kistner RL, Meissner 
MH, Moneta GL, Myers K, Padberg FT, Perrin 
M, Ruckley CV, Smith PC, Wakefield TW. Re­
vision of the CEAP classification for chronic 
venous disorders: consensus statement. J 
Vasc Surg 2004;40:1248-1252.
Prandoni P, Villalta S, Bagatella P, Rossi L, 
Marchiori A, Piccioli A, Bernardi E, Girolami
B, Simioni P, Girolami A. The clinical course 
of deep-vein thrombosis. Prospective long­
term follow-up of 528 symptomatic patients. 
Haematologica 1997;82:423-428.
Porter JM, Moneta GL. Reporting standards 
in venous disease: an update. International 
Consensus Committee on Chronic Venous 
Disease. J Vasc Surg 1995;21:635-45. 
Haenen JH, van Langen H, Janssen MC, 
Wollersheim H, van’t hof MA, van Asten WN, 
Skotnicki SH, Thien T. Venous duplex scan­
ning of the leg: range, variability and repro­
ducibility. Clin Sci (Lond) 1999;96:271-277. 
Haenen JH, Janssen MC, van Langen H, van 
Asten WN, Wollersheim H, van ‘t Hof MA, 
Skotnicki SH, Thien T. The postthrombotic 
syndrome in relation to venous hemodynam­
ics, as measured by means of duplex scan­
ning and strain-gauge plethysmography. 
J Vasc Surg 1999;29:1071-1706.
Klein Rouweler BJF, Brakkee AJM, Kuiper 
JP. Plethysmographic measurement of 
venous flow resistance and venous capacity 
in the human leg. Part one: method. Phlebol- 
ogy 1989;4:241-250.
Zou G. A modified poisson regression ap­
proach to prospective studies with binary 
data. Am J Epidemiol 2004;159:702-6.
Woolf B. On estimating the relation between 
blood group and disease. Ann Hum Gen 
1955;19:251 -253.
Ageno W, Steidl L, Piantanida E. Predictors 
of residual venous obstruction after deep 
vein thrombosis of the lower limbs: a pro­
spective cohort study. Thromb Res 
2003;108:203-207.
Breddin HK, Kadziola Z, Scully M, Nakov R, 
Misselwitz F, Kakkar VV. Risk factors and co­
agulation parameters in relationship to phle- 
bographic response and clinical outcome in 
the treatment of acute deep vein thrombosis. 
Thromb Haem 2003;89:272-277 
Lambert DM, Marceau S, Forse RA. Intra-ab­
dominal pressure in the morbidly obese. 
Obes Surg. 2005;15:1255-1232.
Sugerman HJ. Effects of increased intra-
5
97
CH APTER 5
abdominal pressure in severe obesity. Surg 
Clin North Am 2001;81:1063-1075.
23. Arfvidsson B, Eklof B, Balfour J. Iliofemoral 
venous pressure correlates with intraab­
dominal pressure in morbidly obese patients. 
Vasc Endovasc Surg 2005;39:505-509.
24. Shbaklo H, Holcroft CA, Kahn SR. Levels of 
inflammatory markers and the development 
of the post-thrombotic syndrome. Thromb 
Haemost 2009;101:505-512.
ga
O BES ITY  AN D  THE D E VE LO P M E N T OF PTS
5
99

6
Multilayer compression bandaging in 
the acute phase of deep vein thrombosis 
has no effect on the development of 
the post-thrombotic syndrome
Edith Klappe 
Martin den Heijer 
Janine van Rossum 
Hub Wollersheim 
Carine van der Vleuten 
Theo Thien 
Mirian Janssen
Journal of Thrombosis and Thrombolysis 2009; 27: 400-405
CH APTER 6
Abstract
Objective
The purpose of this randomized study was to evaluate the influence of 
immediate multilayer compression bandages before application of elastic 
stockings in the acute phase of deep vein thrombosis (DVT) on development 
of the post-thrombotic syndrome (PTS).
Methods
Sixty-nine patients with acute symptomatic DVT were randomized to immediate 
bandaging (n=34) or no bandaging (n=35). After reduction of edema 
sized-to-fit elastic stockings were applied in all patients after 7-14 days. 
Follow-up visits and non-invasive examinations were planned after 7, 30 and 
90 days and 1 year. Venous outflow resistance (VOR) was measured by strain 
gauge plethysmography. Thrombosis score (TS) and reflux were measured by 
duplex scanning. After one year patients were evaluated for clinical PTS using 
both the clinical scale of the CEAP classification and the Villalta scale.
Results
Improvement of clinical symptoms and decrease of leg circumference was 
better on day 7 in the bandaging group, but after 1 and 3 months clinical 
symptoms had improved equally in both groups. In 7 patients in the 
no-bandaging group a bandage was applied after all because of persistent 
edema after 10 days. There were no differences in VOR, TS and reflux. Using 
the CEAP classification the incidence of PTS was 39% in patients with 
bandages and 42% in patients without bandages (RR 0.91, 95% CI 0.50-1.66). 
Using the Villalta scale the incidence of PTS was resp. 29% and 33% (RR 0.87 
95% CI 0.41-1.8). There was no difference in severity of PTS.
Conclusion
Immediate multilayer compression bandaging in the acute phase of DVT is 
effective in reducing edema and complaints in the first week, but has no effect 
on thrombus regression, valve incompetence and the development of clinical 
PTS after 1 year.
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Introduction
Deep vein thrombosis (DVT) is a relatively common disease that can be 
associated with acute pulmonary embolism (PE), as well as the more chronic 
post-thrombotic syndrome (PTS). Although it was generally considered to 
take 5-10 years to develop PTS, the current opinion is that PTS already 
becomes clinically manifest within 1-2 years following the acute thrombotic 
event1-3. Impairment of quality of life is correlated with severity of PTS45. 
The pathogenesis of PTS is not completely understood, but it is suggested 
that persistent obstruction and the development of valvular insufficiency after 
DVT leads to venous hypertension, resulting in symptoms like pain and 
swelling of the leg and signs like edema, hyperpigmentation and the occurrence 
of venous ulcers. In a previous study it was shown that the combination of an 
elevated venous resistance, thrombosis score and reflux 3 months after DVT 
could predict PTS with reasonable accuracy2. For this reason preventing valve 
damage and reducing venous hypertension are likely to be important in 
preventing PTS already early in the treatment of DVT.
Outpatient guidelines on treatment of DVT include patient counselling 
regarding low molecular weight heparin (LMWH) injections, oral anticoagula­
tion, ambulation as tolerated and the use of compression stockings with a 
pressure of 30-40 mmHg during 2 years after an episode of DVT. Evidence 
supporting the effectiveness of elastic compressive stockings (ECSs) comes 
from two studies that demonstrated that use of ECSs resulted in a decreased 
incidence of PTS16. As a result of these trials it has become common clinical 
practice to prescribe ECSs for patients with DVT. However, compression 
stocking therapy was delayed for 1-3 weeks, since it takes time to decrease 
the leg swelling and to measure and produce the stockings. In continental 
Europe there is an old tradition to treat mobile patients who have acute DVT 
with multilayer compression bandages. The bandaging has to be done by 
specially trained nurses and is time-consuming while the evidence for this 
therapy remains scarce. Only one small study showed that immediate 
ambulation and compression therapy leads to faster relief of symptoms like 
pain and swelling and a reduction of PTS7.
The hypothesis of this study was that immediate multilayer compression 
bandaging in the first 2 weeks of DVT is effective in reducing symptoms on the 
short term and PTS on the long term, by preventing valve insufficiency and 
stimulation of thrombus regression. To evaluate this hypothesis we performed 
a prospective randomized, unblinded study in which the effect of multilayer
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compression bandaging was compared to no bandaging before application of 
ECSs on clinical symptoms, venous outflow resistance (VOR), thrombosis 
score (TS), reflux and development of clinical PTS after 1 year.
Methods
Patients and study design
Between 2002 and 2004 all consecutive patients with symptomatic DVT, 
confirmed by compression ultrasound, were considered eligible for the study. 
The duration of symptoms ranged from 1 to 90 (mean 8 days). Exclusion 
criteria were previous DVT, pulmonary embolism, a short life expectancy (< 2 
years), paralysis of the leg, pre-existing leg ulcers or signs of venous 
insufficiency, bilateral thrombosis and arterial insufficiency (ABI <0.9). 
The study was part of the Post Thrombosis Study8, in which the role of 
inflammation in the acute phase of DVT is investigated. For this reason patients 
were also excluded because of malignant disease, pregnancy or puerperium, 
use of anti-inflammatory medication or other severe medical illnesses. 
The study was approved by the local ethics committee and all patients gave 
informed consent. Distal DVT was defined as thrombosis of only the calf veins, 
thrombosis of the popliteal vein and higher was defined as proximal DVT.
Patients were treated on the outpatient clinic with LMWH (dose based on body 
weight) and vitamin K antagonists (acenocoumarol, INR 2-3) for 3 months. 
Patients were randomized to multilayer bandaging or no bandaging on the first 
day. Bandages were applied by specialized nurses on the outpatient department 
every 3-4 days.
For distal DVT (over a layer of Tubiton and wadding) inelastic short stretch 
(40 mmHg) bandages (Idealbinde 10 cm X 10 m) were applied on the lower 
leg. Patients wore these bandages day and night and these were changed 
every 3-4 days or when they were too loosened. For proximal DVT the lower 
leg was bandaged the same way, for thigh long stretch bandages (Dauerbinde 
12 cm X 14 m) were used. These long stretch bandages were removed during 
the night. After reduction of edema sized-to-fit graded ECSs were applied in 
both groups after 7-14 days. All patients were equally mobile and encouraged 
to walk as much as possible, leg elevation was advised between ambulation. 
When patients were randomized to no compresssion bandaging but edema 
was persistent after 10 days, compression bandage was applied after all.
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All patients were instructed to wear the stockings for at least 2 years.
Follow-up visits and non-invasive examinations were planned after 7, 30 and 
90 days and 1 year. Clinical scores of symptoms were calculated and 
circumference of the leg was measured 12 cm above knee-joint, 12 cm under 
knee-joint and at the ankle. The difference of circumference between the 
thrombosed and non-thrombosed leg were measured each visit.
Definition of PTS
After 1 year patients were evaluated by a dermatologist who was unaware of the 
results of the venous examination. The severity of PTS was scored according to 
both the clinical score (range 0-6) of the revised CEAP classification (Clinical, 
Etiologic, Anatomic, and Pathophysiologic)9 and the Villalta scale10. In the CEAP 
classification patients with class 0 represent no visible or palpable signs of 
venous disease symptoms of PTS; class 1 telangiectases, reticular veins or 
malleolar flare; class 2 varicose disease; class 3 edema without skin changes; 
class 4 skin changes ascribed to venous disease (4a eczema and pigmentation, 
4b lipodermatosclerosis and atrophie blanche); class 5 skin changes with a 
healed ulcer and class 6 skin changes with active ulceration. PTS was defined 
present if the classification was 3 or more. The Villalta scale grades the severity 
from 0 to 3 of five symptoms (pain, cramps, heaviness, pruritus and paresthesia) 
and six signs (edema, skin induration, hyperpigmentation, venous ectasia, 
redness and pain during calf compression). A summed total score of > 5 
indicates PTS, and >14 or presence of ulcer indicates severe PTS.
Measurement of venous function tests
The VOR was measured in both extremities by strain-gauge plethysmography 
as described previously1112. In summary the patients were examined in supine 
position with pneumatic cuffs around the thighs and strain gauges around the 
calves. After inflation of the cuffs the venous volume increases gradually. 
When maximum volume was achieved, release of cuff-pressure resulted in a 
volume decrease measured by plethysmography. The tangent to the slope of 
the volume decreased was drawn 0.5 seconds after pressure release and the 
slope was converted into a venous emptying rate (VER). This procedure was 
performed at 5 different cuff pressures (50-15 mmHg). Subsequently the 
corresponding VER values were plotted against the effective cuff pressures. 
The slope of the line through the points gives an angle p. In analogy with Ohm’s 
law the VOR was calculated as 1/tangent p. The VOR value is expressed in 
resistance units: mmHg*min/%. In a previous study a VOR exceeding 0.8 
mmHg*min/% was considered abnormal. The non-thrombotic leg was always
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used as control. The reproducibility of the VOR was within 10%12.
Duplex examinations were performed by two experienced vascular technicians 
with a Toshiba SSA 270A scanner with a 3.75 or 5 MHz probe in low flow setting. 
The examination was performed with the patient in a reverse Trendelenburg 
position at 45°, the knees flexed and with the feet resting on a foot-support. 
Sixteen vein segments were examined: the common femoral vein, the femoral 
vein (proximal and middle), the great saphenous vein (proximal, middle and 
distal), the popliteal vein, the small saphenous vein, the posterior and anterior 
tibial veins, the peroneal and gastrocnemial veins. In the calf each artery is 
accompanied by 2 veins; these were numbered: 1 being the most superficial 
and 2 the deeper vein. The distal superficial femoral vein is often not compressible 
because of the anatomical position in the canal of Hunter. After the third month 
the peroneal, gastrocnemial veins and tibial anterior veins were not examined 
because many veins could not be traced and these measurements appeared 
very time-consuming. The results of the remaining 10 vein segments were used 
for analysis. The compressibility was assessed in the transverse plane with 
gentle pressure applied to the overlying skin by the duplex-probe. In the 
longitudinal plane the presence of the Doppler signal was measured. In the 
proximal veins a spontaneous Doppler signal is usually present; in the distal 
veins a flow signal was considered present after gentle squeezing the extremity 
below the level of measurement. The definition of the thrombosis score (TS) was 
based on the description of extent of thrombus and site involvement by Porter 
et al13. A vein segment was considered occluded when the vein segment was 
non-compressible and no Doppler signal was found (TS=2) and non-occluded 
if it was not completely compressible but flow was present (TS=1). A fully patent 
vein segment showed complete compressibility and flow (TS = 0). TS values 
were calculated by counting the TS values of the 10 vein segments. The kappa- 
coefficient of the interobserver variability was 0.7714. Reflux was measured in the 
longitudinal plane. In the proximal veins the Valsalva manoeuvre was used to 
provoke reflux and in the distal veins by manual compression with sudden 
release. Pathological reflux was defined as a reversed flow duration of more 
than 1 s in the proximal veins and more than 0.5 s in the distal veins. The kappa 
of the interobserver variability was 0.8614.
Statistical analysis
We performed a sample size calculation assuming a two-sided p-value of 0.05 
and a power of 80% and SD of 3 to detect a two-point decrease of the Villalta 
scale. This corresponds with a decrease of PTS (Villalta scale > 5) from 25% 
to 15%. This sample size calculation yielded a sample size of 36 patients in 
both groups. Intention to treat and on treatment analysis was performed.
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Results
Sixty-nine patients were randomized to bandaging (n=34) or no bandaging 
(n=35). Idiopathic DVT was present in 42 patients, in 27 patients DVT was 
secondary because of immobilisation (n=11), recent trauma (n= 7) or operation 
(n=9).
Table 1 Baseline characteristics of the patients (intention to treat).
Bandaging No bandaging p-values
Number (%) 31 (48.4) 33 (51.6 )
Age (range) 64 (25-80) 53 (20-86) 0.55
Male/female 15 /  16 17 /  16 0.80
Location of DVT (%)
Distal 4 (6.3) 5 (7.8) 0.79
Proximal: 27 (42.2) 28 (43.8)
Popliteal 5 (7.8) 11 (17.2)
Femoral 3 (4.9) 1 (1.6)
Popliteal and femoral 13 (20.3) 14 (21.9)
Pelvic 6 (9.4) 2 (3.1)
Left 18 (28.1) 19 (29.7) 0.98
Right 13 (20.3) 14 (21.9)
Length in m (range) 1.72 (1.51-1.90) 1.75 (1.53-2.03) 0.58
W eight in kg (range) 73.0 (48.6-103.3) 76.5 (53.0-164.0) 0.57
6
All patients were followed up for at least 12 months. During this period 2 
patients in the bandage group died because of malignant disease, diagnosed 
after inclusion in the study. Two patients were lost to follow up (one in both 
groups). In the control group one patient was not included in the analysis after 
she was diagnosed with a non-Hodgkin lymphoma in her pelvis one week 
after inclusion. Table 1 shows the patient characteristics at baseline. Location 
and extension of thrombosis was equal in both groups.
Improvement of symptoms was better in patients with compression bandages 
on day 7. All patients in the bandaging group had a decrease of symptoms, six 
patients in the no-bandaging group had an increase of symptoms. After 1 and 
3 months symptoms were improved equally in both groups (Figure 1). The 
difference in leg circumference of the thrombosed compared to the healthy
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F igure  1 Decrease of clinical symptoms with and without bandage.
F igure  2 Decrease of leg circumference in centimeters with and without 
bandage.
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leg decreased more rapidly in patients with bandages compared to patients 
without bandages on day 7 and 30 (resp day 7: 1.0 vs 2.75 cm and day 30 -0.5 
vs 2 cm, P<0.05) (figure 2). In seven patients without bandages edema was 
still present after 10 days and compression bandage was applied. Table 2 
shows the mean outcomes of the non-invasive examinations. It demonstrates 
that there were no differences in VOR, TS and reflux between the two groups.
Table 2 Mean (± SD) outcomes of non-invasive venous examinations 
(intention to treat analysis).
Bandaging
N=31
No bandaging 
N =33
P
VOR
Day 7 1.43 (±  1.16) 1.72 (±  1.85) 0.40
Day 30 0.91 (±  0.80) 0.95 (±  0,61) 0.43
Day 90 0.77 (±  0.55) 0.80 (±  0,58) 0.37
Throm bosis score
Day 7 4.11 (±  3.02) 4.33 (±1.41) 0.63
Day 30 2.10 (±  2.38) 2.78 (±1.48) 0.15
Day 90 2.25 (±  1.67) 2.00 (±1.41) 0.90
Reflux
Day 90 1.0 (±  2.14) 0.43 (±  1.13) 0.40
6
Table 3 demonstrates the classification according to the CEAP classification. 
The overall incidence of PTS, defined as CEAP > 3 was 39% in patients with 
bandages and 42% in patients without bandages (RR = 0.92, 95%CI 0.55-1.56). 
When PTS was defined as CEAP > 4 RR was 1.14 (95% CI 0.65-1.99). Using on 
treatment analysis RR for CEAP > 3 and CEAP > 4 were 1.04 and 1.09 
respectively. The overall incidence of PTS, defined as Villalta > 5 was 29% 
in patients with bandages and 33% in patients without bandages (RR 0.87 
95% CI 0.41-1.8). Mean CEAP score after 1 year in patients without bandages 
was 2.15, in patients with bandages 2.12, with a mean difference of 0.22 
(95% CI -0.64 -  0.68). Mean Villalta score after 1 year in patients without 
bandages was 4.09, with bandages 3.74, with a mean difference of 0.35 (95% 
CI -1.47 -  2.16).
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Table 3 Clinical PTS after 1 year (intention to treat).
CEAP Bandaging No Bandaging RR 95% CI
N=31 N =33
0 1 2
1 14 12
2 4 5 0.92* 0.55-1.56
3 4 7 1.14** 0.65-1.99
4 8 7
5 0 0
6 0 0
*RR for PTS defined as CEAP > 3, **  RR for PTS defined as CEAP > 4.
Discussion
There is lack of consensus regarding the optimal timing of initiating of 
compression therapy in the treatment of DVT to prevent PTS. We studied the 
influence of immediate compression bandaging before application of elastic 
stockings in the acute phase of DVT. In the first week bandaging was effective 
in reducing edema and complaints, but after 1 and 3 months improvements 
were equal in both patients with or without bandages. There was no effect on 
thrombus regression, valve incompetence and the development of clinical 
PTS after 1 year.
In acute DVT pain results from an increase of compartmental pressure resulting 
from congestion of muscle veins by thrombi and trapped blood. External leg 
compression has several physical effects. It counteracts edema formation, 
leads to a narrowing of superficial and deep veins and increases blood flow 
velocity in the microcirculation. Partsch et al. demonstrated that compression 
therapy combined with ambulation leads to a faster reduction of leg swelling 
and pain compared to bedrest15. They also showed that multilayer compression 
bandages with high stiffness applied with a pressure higher than 50 mmHg 
have beneficial haemodynamic effects that cannot be achieved by elastic 
compression stockings with a maximum pressure of 30-40 mmHg715. Since 
venous hypertension and valve damage occur soon after a thrombotic episode, 
it is suggested that compression therapy must be applied quickly, but it has
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never been investigated whether immediate compression therapy in the acute 
phase of DVT further reduces the incidence of clinical PTS.
We studied the influence of compression bandaging before application of 
elastic stockings in the acute phase of DVT. Patients in the no-bandaging 
group did not get compression therapy in the first 2 weeks, since it takes about 
two weeks to measure and produce sized-to-fit elastic stockings. Both groups 
received the elastic stockings after 7-14 days. Both groups were treated with 
anticoagulants with a similar INR, also all patients were equally mobile. Like 
the study of Partsch et al. improvement of symptoms and decrease in leg 
circumference was better in patients with compression bandages, although 
after 1 and 3 months symptoms were improved equally in both groups.
There is no objective criterion standard test to diagnose PTS. For clinical 
investigation several scales have been developed. We used both the CEAP 
classification, which describes mainly chronic venous disorders, and the 
Villalta scale which also takes into account subjective symptoms. There was 
no difference in clinical stages of PTS according to neither the CEAP 
classification nor the Villalta scale after 1 year. The incidence of PTS in our 
study did not differ from that observed in large series of patients reported 
previously1.
Both VOR and duplex are non-invasive tests with a good interobserver 
variability and can easily be used in studies and usual patient care1416. 
Previously we demonstrated that the measurement of TS, VOR and reflux at 
three months follow-up can be used as a proxy or surrogate endpoint for PTS2. 
In the current study there was no difference in decline of VOR and TS between 
both groups. This means that compression therapy in the acute phase does 
not induce better thrombus regression compared to only elastic stockings and 
has no influence on the amount of reflux.
This study has some limitations. Firstly randomization was not blind. However, 
the vascular technicians and the dermatologist who classified PTS after 1 year 
were not informed. Secondly, no objective, gold standard test to diagnose 
PTS exists. For this reason we used objective non-invasive techniques as VOR 
and duplex. The disadvantage of the CEAP classification is that it is rather 
static, description of changes over time is limited and subjective symptoms 
are not included17. For this reason we also used the Villalta scale. Both PTS 
classification systems reasonably correlated with the ambulant venous 
pressure (AVP)18. Finally seven patients of the no-bandaging group received
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bandaging after all because of persistent swelling and pain. For this reason 
both on-treatment as intention-to-treat analysis were performed, with same 
results.
Based on the results of our study immediate compression bandaging in the 
acute phase of DVT reduces pain and leg circumference significantly, but it 
has no additional value compared to delayed compression therapy with 
stockings concerning regression of thrombus, development of reflux and 
clinical PTS. Therefore, in practice, applying elastic stockings within about 2 
weeks seems sufficient. Immediate compression therapy with multilayer 
bandaging should only be applied to patients with severe complaints or 
swelling of the thrombosed leg.
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Summary
The main objective of this thesis was to obtain insight in the role of inflammation 
in the pathophysiology of the post-thrombotic syndrome (PTS). Other 
objectives were to examine the predictive value of non-invasive venous 
examinations for PTS, obesity as a risk factor for PTS and the effect of 
immediate bandaging in acute deep vein thrombosis (DVT) on the development 
of PTS.
In the first study, described in chapter 2, we investigated the predictive value 
of non-invasive venous examinations in the initial phase of DVT for the 
development of PTS. In 93 patients with a first DVT the thrombosis score (TS), 
reflux, venous outflow resistance (VOR) and calf muscle pump function (CMP) 
were examined prospectively using duplex and plethysmography. PTS was 
evaluated after one, two and six years. The prognostic value to predict PTS 
was highest for the combination of TS, VOR and reflux measured three months 
after diagnosis of DVT with an area under the curve (AUC) of 0.77 (0.65-0.90) 
for PTS after one year. We also found that the incidence of PTS after DVT did 
not increase significantly after one year, whereas during longer follow-up (two 
and six years) in patients with PTS only the severity of PTS rose.
In the past several studies have shown a relationship between inflammation 
and DVT, yet it was unclear whether inflammation was a risk factor for or a 
result of the DVT. In human studies elevated markers were found after a 
thrombotic event. In chapter 3 we have described that concentrations of 
inflammatory markers like IL-6, IL-8 and CRP were elevated in the acute phase 
of DVT and subsequently decreased in the next days, suggesting that the 
acute thrombusformation in DVT causes an inflammatory response.
Based on these findings a prospective study, described in chapter 4, was 
performed in 110 patients with a first period of DVT to examine whether 
inflammatory markers like IL-6 and CRP are associated with elevated VOR, TS, 
reflux and PTS. Elevated levels of inflammatory markers were related to 
elevated outcomes of VOR and TS after three months; VOR and TS were 
related to the incidence of PTS after one year. The association of IL-6 and CRP 
with PTS was weak or absent depending on the PTS-scale. No associations 
were found with reflux. These results suggest that inflammation might play a 
role in incomplete thrombusclearance, in venous outflow obstruction and in 
the development of PTS after one year.
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In the study described in chapter 5 we demonstrated that obesity is associated 
with a higher risk of PTS. Because the mechanism that relates obesity to PTS 
is unknown we investigated the relation between obesity and other determinants 
of PTS. A clear relationship between obesity and VOR and a weak relation with 
inflammatory parameters was found. There was no relation with reflux or 
residual thrombus (as reflected by the thrombosis score). In the meta-analysis 
a BMI > 30 was associated with an increased risk for PTS (RR 1.4 (95% CI 
1.20-1.65). The most likely explanation is that in obesity an increased intra­
abdominal pressure results in elevated VOR with subsequently increased 
venous pressure in the extremities.
The last aim of this thesis (described in chapter 6) was to investigate the effect 
of immediate compression bandaging in DVT in relation to the development of 
PTS. 69 Patients were randomized to immediate bandaging or no bandaging 
before application of a sized-to-fit elastic stocking. Improvement of clinical 
symptoms and the decrease of leg circumference were better in the bandaging 
group after one week of follow-up. There were no differences between the 
group with immediate bandaging and the no bandaging group in non-invasive 
venous function measurements (VOR, TS and reflux) during follow-up and in 
the incidence of PTS after one year.
In conclusion, inflammation and obesity are risk factors for the development of 
PTS after DVT. Immediate compression bandaging is of no preventive value on 
the long term.
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General discussion
The pathophysiology of PTS is not completely unraveled. The clinical 
manifestations of PTS are probably the result of venous hypertension, which 
occurs as a consequence of persistent deep vein outflow obstruction, of 
venous valvular incompetence or a combination of both.
Obstruction is caused by incomplete recanalization of the thrombosed vein 
segment and can be measured by ultrasound as residual thrombus or residual 
vein thrombosis. The capacity of the (partially) obstructed veins to empty the 
venous system is reduced, resulting in a higher venous pressure. Yet, the 
presence of residual thrombosis alone is only modestly associated with the 
development of PTS12. Competent valves ensure the direction of blood flow to 
the heart, activated by muscular contraction during walking, thereby reducing 
the venous pressure in the leg. Incompetent valves permit the blood flow to 
leak backwards and reduce the emptying of the venous system. This results in 
venous hypertension with higher than normal venous pressures, which remain 
elevated for prolonged periods3.
The main aim of this thesis was to investigate the role of inflammation in the 
pathogenesis of PTS. Since thrombosis and inflammation are related, it could 
be hypothesized that inflammation in DVT is involved in the changes of the 
vein wall and of the valves resulting in the development of PTS.
Other objectives were to examine the predictive value of non-invasive venous 
examinations for PTS, the importance and the mechanism of obesity as a risk 
factor for PTS and the effect of immediate bandaging in acute DVT on PTS.
The value of non-invasive venous measurements after DVT
As explained in the introduction several methods can be used to examine the 
venous system to document and quantify the presence of obstruction, reflux 
or both. Duplex (for measurement of reflux and thrombosis score) and 
plethysmographic measurements (VOR) were performed in former studies in 
our hospital.
In this thesis we have shown that already three months after DVT PTS could be 
predicted with reasonable accuracy with VOR, reflux and thrombosis score 
(reflecting residual thrombosis). As mentioned above, the association of 
residual thrombosis with a higher incidence of PTS is moderate124. Residual 
thrombosis results in persistent venous outflow obstruction, but extra blood
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flow through collateral veins can probably compensate this obstruction 
partially. The net result determines the venous outflow resistance. In the 
studies described in this thesis we found a clear association of elevated VOR 
and PTS. A similar study however did not show a predictive value of the VOR 
in the univariate analysis, but only a minor improvement of the area-under-the- 
curve in a multivariate model4. Reflux as a risk factor for PTS, alone or in 
combination with obstruction, is confirmed in several other studies4-6.
Because of the complexity of the venous system itself and the changes after 
DVT it is important to measure several venous parameters. This is probably 
the explanation that the combination of VOR, reflux and thrombosis score had 
the best accuracy. Duplex measurements are widely available in almost all 
hospitals in contrast to the plethysmograph for measurement of VOR. Reflux 
and thrombosis score without VOR had only a little lower accuracy than in 
combination with VOR.
A clinical implication might be to perform a duplex in patients three months 
after diagnosis of DVT. One argument is to identify patients at risk for PTS; 
these patients should probably be extra motivated to wear their elastic 
stockings. Another argument is that residual thrombosis indicates a 
prothrombotic state and is associated with higher risk of recurrence7-10. This 
could have implications for the duration of anticoagulation. In a randomized 
trial, tailoring the duration of anticoagulation on the basis of ultrasonography 
findings reduced the rate of recurrent VTE in adults with proximal DVT11. The 
Prolong trial however showed conflicting results. Residual venous thrombosis 
was not a risk factor for recurrent VTE but elevated D-dimer 1 month after an­
ticoagulation withdrawal was. The predictive value of D-dimer and residual 
venous thrombosis for recurrence will probably be a matter of debate in the 
next years12.
A third argument for performing a duplex after three months is the benefit in 
the diagnosis of recurrent DVT in the follow-up. In case of suspicion of recurrent 
DVT abnormalities of the duplex can be compared to the previous duplex 
measurement. Ultrasonographic criteria for recurrent ipsilateral thrombosis 
are incompressibility of a proximal vein segment initially free of thrombi or in­
compressibility of a proximal vein that showed complete recanalization13.
Inflammation in the pathophysiology of PTS
The main purpose of the studies presented in this thesis was to examine the 
role of inflammation in the pathogenesis of PTS. The destruction of venous
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valves and persistent outflow obstruction might be caused by the volume 
effect of the thrombus, but also by an inflammatory process which accompanies 
thrombosis. Studies in animals showed that inflammation in DVT involves both 
the venous vascular wall and the perivascular area14. Several clinical studies 
examined the role of inflammation in the pathogenesis of venous thromboem­
bolism but not of PTS.
Our hypothesis was that inflammation in the acute phase of DVT is important 
in the development of PTS. The inflammatory response in the thrombus and 
vein wall may lead to decreased thrombusclearance, vein wall fibrosis and 
destruction of the venous vessel valves resulting in valvular insufficiency. This 
hypothesis is partially confirmed by the findings in this thesis as there was an 
association of inflammatory markers with the thrombosis score (decreased 
thrombusclearance), elevated venous outflow obstruction (VOR) and PTS. 
However, no direct association with reflux was found.
Only one other study reported an association of IL-6 and PTS. In a Canadian 
study in 307 patients with DVT IL-6 and intercellular adhesion molecule-1 
(ICAM-1) were measured four months after diagnosis of DVT (instead of 
measurement at diagnosis as in our study). Mean levels of IL-6 and ICAM-1 
were significantly higher in patients with PTS compared to patients without 
PTS. Other markers of inflammation, like IL-8, IL-10 and monocyte chemotactic 
protein-1 (MCP-1) showed no association with PTS. In line with our study 
markers of inflammation did not differ between patients with the presence or 
absence of reflux. In patients without valvular reflux median levels of IL-6 were 
higher in patients with PTS than in patients without PTS15.
It is likely that two processes are involved in the development of PTS. The 
inflammatory process caused by the thrombus is necessary to start the 
process of thrombus resolution. Leucocytes invade the thrombus in a specific 
sequence, with an early influx of neutrophils followed by monocytes16. 
Neutrophils promote both fibrinolysis and collagenolysis17. Monocyte influx 
peaks at day 8 after thrombogenesis and is essential for DVT resolution. The 
process in the vein wall is similar and promotes increased fibrosis of the vein 
wall18. Residual thrombus (as a result of incomplete thrombusclearance) and 
vein wall fibrosis lead to increased outflow obstruction. Reflux is the result of 
direct damage to the valves by the thrombus itself or by entrapment in the 
fibrotic process of the vein wall. Both persistent obstruction and reflux because 
of valvular insufficiency lead to venous hypertension and PTS (see figure 1).
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F igure  1 Hypothetical development of PTS.
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DVT causes obstruction and initiates an inflam matory response resulting in (incomplete) 
thrombusclearance, vein wall changes and fibrosis resulting in persistent obstruction. Direct 
mechanical damage to the valves might cause reflux of the valves. Both obstruction and reflux 
lead to venous hypertension and PTS. The high venous pressure causes dilatation and 
distortion of the valve resulting in progressive reflux.
Subsequently, venous hypertension leads to further alterations of the venous 
system. Elevated venous pressure causes dilatation and distortion of the valve, 
preventing proper closure of the leaflets, disturbing the flow patterns within 
the valve and allowing reflux19. In animal models an acute increased venous 
pressure stretched the valves directly. Subsequently reflux occurred not 
immediately but started after at least two days and then increased over time. 
After three weeks, the numbers of granulocytes, monocytes, macrophages, 
and lymphocytes were increased within the pressurized valves. Morphologic 
changes like leaflet height and width in the valves also occurred and some 
valves disappeared. These studies suggest that valves can tolerate high 
pressures for limited periods, but when there is prolonged pressure-induced 
inflammation, valve remodelling and loss and reflux occur3.
In our six-year follow-up study we found that after one year not the incidence 
but the severity of PTS increased. In a study on progression of chronic venous 
disease, progression in post-thrombotic limbs was more rapid compared with 
patients with primary chronic venous insufficiency20. This difference may be
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explained by the underlying pathophysiology. Reflux is the main contributing 
pathology in primary disease, while in post-thrombotic legs reflux is combined 
with outflow obstruction, contributing to a higher venous hypertension. Another 
explanation is that refluxing blood from the superficial veins can be 
accommodated by the normal deep venous system, while in post-thrombotic 
legs venous return is more limited by the obstructed deep veins20.
Assuming inflammation plays an important role in the pathogenesis of PTS, 
inhibition of inflammation in the acute phase of DVT could reduce the incidence 
of PTS. At this moment the standard treatment of DVT is anticoagulation with 
Low Molecular Weight Heparin (LMWH) for at least five days and coumarines 
for at least three months. Addition of anti-inflammatory medication might 
decrease the development of PTS both by inhibition of inflammation of the 
vein wall and by inhibition of coagulation. These days a wide selection of anti­
inflammatory medicines are available. The most widely used types of anti-in­
flammatory drugs are non-steroidal anti-inflammatory drugs (NSAID’s). In the 
treatment of superficial thrombophlebitis NSAID’s have been prescribed to 
reduce the extension of inflammation and the recurrence of thrombotic events 
in patients experiencing superficial venous thrombosis (SVT)21. No data exist 
for the treatment of acute DVT. Because of the gastro-intestinal bleeding risk 
NSAID’s are relatively contra-indicated in combination with anticoagulation. 
An increase of cardiovascular events was observed in a large colorectal cancer 
prevention trial with celecoxib compared to placebo, reason to discontinue the 
study22. As treatment with anti-inflammatory medication can probably be 
limited to a short period of time (2-5 days) the risk of bleeding and/or 
cardiovascular events is probably limited. An alternative to NSAID’s could be 
a short period of corticosteroids. High dose of glucocorticoid therapy is 
associated with different types of venous thrombotic events23, but the assumed 
prothrombotic effect could be also be the result of the underlying disease for 
which steroidtherapy is indicated24. Nevertheless, additional treatment with 
NSAID’s or steroids should only be evaluated in the context of a prospective 
randomized controlled study.
LMWH’s also have anti-inflammatory properties. In experimental animal 
studies enoxaparin decreased both thrombus burden and inflammation25. 
Treatment with enoxaparin (LMWH) compared to coumarines resulted in lower 
residual thrombosis after three months, but the incidence of PTS after five 
years was similar between both treatment groups, perhaps due to a small 
sample size26.
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Recently several new agents for the treatment for venous thromboembolism 
(VTE) have been introduced such as thrombin- and factor Xa inhibitors. Until 
now in studies regarding anticoagulation, like the type of anticoagulation, 
duration or intensity, PTS is not taken into account as an endpoint for treatment 
of DVT.
In conclusion, DVT leads to an inflammatory process, outflow obstruction and 
reflux resulting in venous hypertension. Elevated venous pressure leads to 
altered flow through collaterals, dilatation of veins and distortion of valves. 
Subsequently this results in progressive valvular incompetence and eventual 
valvular destruction. Inhibition of inflammation in the acute phase of DVT could 
reduce the incidence of PTS. More research is needed to advocate studies 
with inhibition of the inflammatory response to reduce PTS.
Obesity as risk factor for PTS
Several risk factors for PTS have been identified and ipsilateral recurrent DVT 
is by far the most important risk factor27. Several studies reported that obesity 
-  as reflected by the body mass index (BMI) -  is associated with the development 
of PTS but the pathophysiology of this relationship is unclear. In this thesis we 
have shown that patients with obesity have a higher VOR and subsequently a 
higher risk of developing PTS after DVT. Obesity was not related with reflux or 
residual thrombosis (reflected as thrombosis score). In the meta-analysis a 
BMI > 30 was associated with an increased risk of PTS.
Several mechanisms may explain the relationship between BMI and VOR. A 
possible explanation is that obesity is associated with a chronically increased 
intra-abdominal pressure (IAP)28 29. In animal studies an increased IAP induced 
a higher femoral venous pressure28. This was also demonstrated in obese 
patients. The increased IAP caused an elevated iliofemoral venous pressure, 
which transmits via incompetent femoral veins, causing venous stasis in the 
lower limbs30. These findings are consistent with results from studies in patients 
with primary venous insufficiency and obesity. In morbidly obese patients an 
increasing CEAP-class was correlated with an increase of mean BMI, although 
two thirds of the limbs had no anatomical evidence of venous disease31. In 
addition, the CEAP clinical stage was more advanced in obese patients than 
non-obese patients with comparable anatomical patterns of venous 
incompetence32. This may be the result of raised intra-abdominal pressure, 
leading to an increased venous pressure33. Although not significant, in the 
non-thrombotic leg there was also a trend of higher VOR with obesity.
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Another explanation is that in obese patients the inflammatory response is 
increased and/or prolonged. In the past years it has become clear that adipose 
tissue, apart from its classical role as an energy storage depot, is also a major 
endocrine organ secreting many factors and cytokines. In obese patients 
higher levels of IL-6, CRP and TNF were measured34-36. The increased 
inflammatory response may lead to an increase of vein wall fibrosis and venous 
outflow obstruction. Still, in our study we found only a weak relationship 
between BMI and inflammatory parameters.
BMI was not related with reflux nor with residual thrombosis (reflected as 
thrombosis score). This is in agreement with data from other studies, that 
showed no differences in BMI between patients with or without thrombus- 
regression3738. In the meta-analysis the relative risk for PTS was 1.4 for patients 
with a BMI > 30 kg/m2. Because the incidence of obesity is increasing and 
obesity is a risk factor for initial and recurrent DVT39 40, this finding is 
important.
To reduce the incidence and the severity of PTS, it is reasonable that patients 
with obesity and DVT should be encouraged to a strict application of preventive 
measures (including wearing appropriate stockings) and weight reduction. 
Compression stockings reduced the incidence of PTS with 50% in all patients 
with DVT. It is unknown whether this reduction is associated with BMI. It seems 
likely that obese patients profit more from compression stockings than lean 
patients.
Weight reduction would have several beneficial effects. At first, weight 
reduction leads to less venous symptoms. A population study showed an 
inverse relationship of BMI with blood flow velocity at rest41. In morbidly obese 
bariatric surgery improved venous symptoms. Bladder pressures as a 
surrogate for intra-abdominal pressure normalized after gastric bypass 
surgery42. Secondly, several studies reported a decrease of several 
inflammatory parameters with weight loss. The results however are conflicting. 
Most studies found a decrease of CRP levels with weight loss but contradictory 
results are reported regarding IL-6 and TNF. Explanations for this discrepancy 
are differences in the kind of treatment, the amount of weight loss and the 
duration of follow-up36. Finally, weight reduction may lead to a lower risk of 
recurrence of VTE since obesity is a risk factor for initial VTE39 and recurrent 
VTE40.
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In conclusion, obesity is a risk factor for PTS. Obesity was not related with 
thrombus regression and reflux. In obesity VOR is more elevated probably 
because of an increased intra-abdominal pressure and because of increased 
vein wall changes as a result of an elevated inflammatory response. The 
potential role of weight reduction in the prevention of both PTS and recurrent 
DVT should be evaluated.
The effect of immediate compression therapy
Next to treatment with anticoagulants patients with DVT are treated with 
compression therapy. The long term use of elastic stockings after symptomatic 
DVT has been evaluated in three trials. The results have been pooled in a 
meta-analysis that showed a substantial risk reduction of PTS (Odds ratio 0.3; 
95% CI 0.20 tot 0.48)43. Both in the guidelines of the American College of Chest 
Physicians as in the last Dutch CBO guidelines elastic stockings (class 3 30-40 
mmHg) are recommended for at least 2 years. Normally compression stocking 
therapy is delayed for 1-2 weeks since it takes time to decrease leg swelling 
and to measure and produce the stockings. In continental Europe there is a 
tradition to treat mobile patients with DVT with multilayer compression 
bandages. The bandaging has to be applied by specially trained nurses and is 
time-consuming while the effect in the treatment of DVT is relatively unknown. 
Only one small study showed that immediate ambulation and compression 
therapy - compared to bed rest and no compression - leads to a faster relief of 
symptoms like pain and swelling and to reduction of PTS44. Our hypothesis 
was that immediate bandaging would result in further reduction of PTS, but 
this appeared not to be the case. The only effect of immediate bandaging was 
reduction of edema and complaints. No effect was observed in venous outflow 
obstruction, valvular insufficiency or thrombus resolution.
The precise mechanism by which stockings reduce the risk for the post- 
thrombotic syndrome is unknown. It has been suggested that elastic 
compression stockings (ECS) assist the calf muscle pump, reduce venous 
hypertension and valvular reflux, and consequently reduce edema, improve 
tissue microcirculation, and prevent skin breakdown4546. In one of the RCT’s of 
elastic stockings no differences were seen in vein abnormalities between 
those who had or had not received the prescription of elastic stockings2. In the 
other RCT’s of elastic stockings no venous examinations were performed. One 
could hypothesize that the effect of stockings is primarily inhibition of the 
translation of venous hypertension in the venous system to the surrounding 
tissues but without improvement of thrombusclearance or prevention of 
valvular insufficiency. If this is the case, the effect of extending one or two
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weeks of compression therapy with bandages before stockings are applied 
could be too small to detect on the long term.
The application of compressive bandages is difficult and time-consuming and 
can only be applied by specialized nurses. As a result of our study we advise 
that the use of these bandages may be abandoned. Only for patients with 
severe pain and/or persistent edema or with prior venous insufficiency, 
application of a bandage can be considered. For clinical practice application 
of a tubular compression bandage (Tubigrip) may provide the patient the same 
feeling of comfort and confidence that allows the patient to start his early 
mobilisation. This Tubigrip can be removed during nights and showering, thus 
providing even more comfort to the patient.
After reduction of edema elastic stockings are advised for all patients. The 
question is how long the stockings should be worn. At this moment stockings 
are advised for a period of at least two years based on current evidence of 
the trials that evaluated the use of stockings for 2 years or longer. A recent 
trial reported that prolongation of stockings after 6 months for an additional 
18 months showed no clear benefit in the absence of PTS after 6 months47. 
We suggest a more patient-tailored recommendation on the duration of 
stockings by considering risk factors like residual thrombus, BMI and 
complaints of PTS.
Conclusion
In conclusion, PTS is an important complication of DVT and the importance 
both clinically and scientifically is relatively underestimated. In this thesis we 
have shown that non-invasive venous measurements can predict PTS with 
reasonable accuracy. The association between inflammation and PTS needs 
to be further elucidated to identify new therapeutic anti-inflammatory strategies 
for prevention of PTS. Obesity -  as reflected by the body mass index (BMI) -  is 
a risk factor for PTS. The importance of weight reduction in reducing PTS 
should be evaluated. Finally, initial bandaging in acute DVT is not effective in 
reducing PTS on the long term and may be abandoned except for patients 
with heavy complaints and edema.
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Samenvatting
Het post-trombotisch syndroom (PTS) is een combinatie van klachten die bij 
patiënten blijven bestaan na een diepe veneuze trombose (DVT). De incidentie 
van DVT is 1 patiënt per 1000 per jaar en de diagnose wordt zowel in de huis­
artspraktijk als in het ziekenhuis geregeld gesteld. De behandeling met 
antistolling is gericht op vermindering van acute symptomen en het voorkómen 
van longembolieën. Op de lange termijn echter houdt 20 tot 50% van de 
patiënten restverschijnselen aan het been, ook wel PTS genoemd. Deze 
klachten variëren van pijn, krampen en oedeem tot huidveranderingen zoals 
hyperpigmentatie, lipodermatosclerose en een veneus ulcus (open been). 
Behalve soms ernstige morbiditeit gaat dit ook gepaard met verlies van 
kwaliteit van leven en hoge kosten in de gezondheidszorg.
De klinische manifestaties zijn waarschijnlijk het gevolg van veneuze 
hypertensie als gevolg van klepinsufficiëntie (reflux), van persisterende 
obstructie van de vene of een combinatie van deze factoren. Er zijn echter nog 
veel onduidelijkheden over de precieze pathogenese.
Het belangrijkste doel van de studies beschreven in dit proefschrift is meer 
inzicht te krijgen in de rol van ontsteking in pathogenese van PTS. Daarnaast 
zijn de resultaten beschreven van onderzoeken naar de voorspellende waarde 
van niet-invasief vaatfunctie-onderzoek, obesitas als risicofactor voor PTS en 
het effect van zwachtelen in de acute fase van DVT.
In de eerste studie, beschreven in hoofdstuk 2, is onderzocht of met 
niet-invasief vaatfunctie-onderzoek het ontwikkelen van PTS na DVT voorspeld 
kon worden. Gedurende 6 jaar werden 93 patiënten met DVT vervolgd. Naast 
de veneuze weerstandsmeting en de kuitspierpompfunctie werden reflux en 
de trombosescore gemeten. De trombosescore kan beschouwd worden als 
maat voor de hoeveelheid resttrombus bij onvoldoende rekanalisatie van de 
vene. Na 1, 2 en 6 jaar werden de patiënten beoordeeld door een dermatoloog 
op de aanwezigheid van PTS. De combinatie van de veneuze weerstands­
meting, trombosescore en reflux gemeten na drie maanden bleek een redelijk 
goede voorspellende waarde te hebben voor het ontwikkelen van PTS. De 
voorspellende waarde van de kuitspierpompfunctie alleen of in combinatie 
met de andere testen, was laag. In deze studie bleek ook dat de incidentie van 
PTS na 1 jaar (49%) nauwelijks meer verder steeg, maar wel dat de ernst van 
PTS toenam.
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Bij studies naar PTS zouden de niet-invasieve vaatfunctie-onderzoeken zoals 
de veneuze weerstandsmeting en thrombosescore na drie maanden als 
surrogaat eindpunt gebruikt kunnen worden. Met de duplex wordt hierbij 
tegelijkertijd informatie verkregen over de aanwezigheid van resttrombus. 
Deze informatie kan nuttig zijn bij verdenking recidief of titreren van duur van 
anstistolling (indien dit zinvol blijkt).
Meerdere studies hebben een relatie aangetoond tussen ontsteking en DVT. 
Bij patiënten na een doorgemaakte DVT werden verhoogde ontstekings- 
markers in het bloed gemeten. Hieruit werd afgeleid dat ontsteking een 
risicofactor was voor het ontstaan van DVT. Het was onduidelijk of ontsteking 
een oorzaak of gevolg was van de trombose. De studie beschreven in 
hoofdstuk 3 bestond uit het onderzoeken van deze ontstekingsreactie in de 
acute fase van DVT. Bij patiënten met verdenking DVT werden de ontstekings- 
parameters Interleukine-6 (IL-6), Interleukine-8 (IL-8) en C-reactive protein (CRP) 
gemeten. In vergelijking met de patiënten bij wie DVT werd uitgesloten, werden 
bij patiënten met DVT verhoogde concentraties van de ontstekingsparameters 
gemeten. Deze concentraties namen af in de volgende dagen. Het beloop van 
deze concentraties suggereert dat de ontsteking een gevolg is van DVT.
In hoofdstuk 4 zijn de resultaten van de prospectieve studie beschreven, met 
als belangrijkste vraag of ontstekingsmarkers op het moment van diagnose 
van een DVT geassocieerd waren met de veneuze weerstand, trombosescore, 
reflux en uiteindelijk PTS. In deze studie zijn 110 patiënten met een 
idiopathische DVT onderzocht, waarbij in de acute fase parameters van 
ontsteking (IL-6 en CRP) gemeten zijn in het bloed. De patiënten zijn gedurende 
een jaar vervolgd met niet-invasief vaatfunctie-onderzoek en met bloedafnames 
ter bepaling van de ontstekingsparameters. Na een jaar zijn de patiënten 
beoordeeld door een dermatoloog op klachten en symptomen van PTS.
Patiënten met hoge concentraties van IL-6 en CRP bij diagnose hadden een 
grotere kans om na drie maanden nog een verhoogde veneuze weerstand te 
hebben evenals een verhoogde trombosescore. Patiënten met een verhoogde 
veneuze weerstand en verhoogde trombosescore na drie maanden bleken 
een duidelijk verhoogd risico op PTS na een jaar te hebben. De relatie tussen 
IL-6 en CRP bij diagnose en PTS na 1 jaar bleek zwak of afwezig, afhankelijk 
van de definitie die gebruikt werd voor het vaststellen van PTS. Gezien de 
duidelijke relatie tussen de ontstekingsparameters en de veneuze vaatonder- 
zoeken na drie maanden enerzijds, en tussen de veneuze vaatonderzoeken en 
PTS anderzijds, ondersteunen deze resultaten de hypothese dat ontsteking in
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de acute fase bijdraagt aan het ontstaan van PTS na DVT. Er bleek geen goede 
relatie te zijn tussen IL-6 en CRP en het ontwikkelen van reflux. Mogelijk zijn 
hier andere mechanismen in het spel zoals directe beschadiging van de 
kleppen door de trombus of het optreden van veneuze dilatatie, waardoor de 
kleppen niet meer goed kunnen sluiten.
Op grond van deze bevindingen lijkt het waarschijnlijk dat DVT leidt tot een 
ontstekingsreactie, die in eerste instantie nodig is om voor trombusresolutie 
en rekanalisatie. Deze ontstekingsreactie vindt niet alleen plaats in de trombus 
maar ook in de vaatwand en gaat gepaard met het optreden van fibrose van 
de vaatwand. Persisterende obstructie is het gevolg van incomplete trombus­
resolutie en vaatwandveranderingen en leidt tot veneuze hypertensie. Dit kan 
vervolgens leiden tot veneuze dilatatie, met als gevolg het niet goed sluiten 
van kleppen en uiteindelijk klepveranderingen.
Als ontsteking een rol speelt in de pathogenese van PTS, zou remming van 
deze ontsteking tot een vermindering van PTS kunnen leiden. Mogelijkheden 
hiervoor zijn het geven van ontstekingsremmers zoals niet-steroide ontstekings- 
remmende medicatie (NSAID’s) of prednison gedurende een aantal dagen. 
Ook langdurige behandeling met laag moleculair heparine (LMWH) is een 
mogelijkheid, omdat LMWH ook ontstekingsremmende eigenschappen bezit. 
Het effect hiervan moet geëvalueerd worden in prospectieve klinische studies.
In hoofdstuk 5 is beschreven dat in de bovengenoemde studie, bij patiënten 
met obesitas (BMI > 30) een hogere incidentie PTS werd gevonden dan in 
patiënten met een normale BMI. Om meer inzicht te krijgen in de pathofysiolo- 
gie hebben we gekeken naar het effect van BMI op andere parameters. Er was 
een zwakke associatie van BMI met ontstekingsparameters. Bij een hogere 
BMI bleek een duidelijk verhoogd risico op een persisterend verhoogde 
veneuze weerstand na drie maanden. Ook in het gezonde been was de 
veneuze weerstand bij een hogere BMI hoger dan in de patiënten zonder 
overgewicht. Deze hogere veneuze weerstand is meest waarschijnlijk het 
gevolg van een hogere abdominale druk. Er bleek geen relatie tussen BMI en 
de trombosescore en reflux. In meerdere studies is een associatie beschreven 
tussen obesitas en PTS. In de meta-analyse was obesitas (BMI > 30) een 
risicofactor voor PTS.
Bij patiënten met obesitas is de compliance bij het dragen van de elastische 
kousen waarschijnlijk erg belangrijk. Compressietherapie is tot dusver de 
enige bewezen (therapeutische) maatregel die de kans op PTS reduceert.
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Daarnaast moet gewichtsreductie worden nagestreefd.
Het onderzoeken van het effect van zwachtelen in de acute fase van DVT is 
beschreven in hoofdstuk 6. Naast het geven van antistolling worden patiënten 
met DVT behandeld met compressietherapie door middel van elastische 
kousen. Het gebruik van kousen gedurende 2 jaar na een trombosebeen leidt 
tot ongeveer een halvering van het risico op PTS. Het was echter onduidelijk 
of het onmiddellijk starten van compressietherapie door middel van zwachtelen 
nog een verdere afname zou geven. Om dit te onderzoeken werden 69 
patiënten gerandomiseerd tussen wel of niet zwachtelen voorafgaand aan het 
dragen van een elastische kous. Er werd wel een snellere verbetering van 
klachten en zwelling gevonden na een week, maar deze verschillen waren na 
een maand verdwenen. Ook was er geen verschil in de groepen wat betreft 
veneuze weerstand, trombosescore, reflux na drie maanden en PTS na 1 jaar.
Wat betreft het gebruik van zwachtels is ons advies het standaard gebruik van 
zwachtels af te schaffen, omdat het geen effect heeft op het verminderen van 
PTS. Het aanleggen van een compressieve zwachtel vereist een goede 
techniek van speciaal daarvoor getrainde verpleegkundigen op de polikliniek 
of thuiszorg en is daarmee kostbaar. Op indicatie zoals bij patiënten met veel 
pijn, persisterend oedeem of al bestaande veneuze insufficiëntie kan het nog 
toegepast worden. Een simpel alternatief is mogelijk het gebruik van 1 of 2 
lagen Tubigrip, die ’s nachts en bij douchen kan worden verwijderd.
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Terugblik
Tien jaar heeft het geduurd, maar nu is het proefschrift af! Bij de terugblik op 
deze jaren komt blijdschap en groot verdriet naar boven. Het verdriet van het 
verlies van een aantal geliefde personen in een jaar (en een dag) tijd. Op 26 
september 2005 overleed Marc, mijn man en vader van Bram en Tim, volledig 
onverwacht aan een hersenbloeding. Bijna een jaar later overleed mijn vader, 
Paul Klappe (t 15 september 2006) eveneens plotseling. Ten slotte overleed 
op 27 september 2006 Lieke Hoogendoorn, collega-internist en vriendin. Ik 
zou ze dit nog willen zeggen.
Marc, we hadden het goed samen en waren vol met plannen voor de toekomst, 
zoals zeilen en reizen met de kinderen. We waren trots op onze kinderen, ons 
bootje en op ons plezier in het werk, jij als huisarts en ik als internist. Terwijl ik 
op de laptop met een volgende versie van een manuscript voor het proefschrift 
bezig was, zag ik dat je onwel werd. Diezelfde nacht ben je overleden, ik had 
nog zoveel willen zeggen. Marc, ik mis je. Ik wil je danken voor jouw liefde 
voor mij en de kinderen en ik wil je zeggen dat je enorm trots kunt zijn op onze 
kinderen. Marc, het boekje is nu af!
Pap, ik heb altijd bewondering gehad voor de manier waarop je na je CVA met 
je beperkingen bent omgegaan en hoe je me gesteund hebt na het overlijden 
van Marc. Trots was je op de reiger die je gemaakt had als cadeau voor mijn 
promotie, ik was immers al een heel eind. Je had fo to ’s laten zien aan Marc, 
de avond voor hij overleed. Ik heb hem gekregen voor mijn eerste verjaardag 
zonder Marc en achteraf de laatste verjaardag met jou. Ik denk dat je zelf ook 
wel inzag dat het met de promotie nog wel even ging duren. De reiger staat nu 
trots naast Marc’s foto. Pap, het boekje is nu af!
Lieke, een paar weken na het overlijden van Marc werd je ziek en volgde een 
strijd, die je na een schijnbare overwinning toch verloor. Dat je bijzonder was, 
wist ik al. Door de verhalen, bezoeken aan Hazerswoude en vakanties in Flims 
heb ik bewondering gekregen voor de manier waarop je in het leven stond en 
je strijd hebt gevoerd. Het voelt goed om nu het leven te delen met Frank en 
jullie kinderen, Nikki en Roos, daar ben ik enorm dankbaar voor. Lieke, jouw 
boekje kwam niet af helaas, maar Frank heeft me gestimuleerd om dit boekje 
af te maken!
Blijdschap komt ook naar boven. Blij en trots ben ik op de manier, waarop ik in 
eerste instantie met Bram en Tim het leven met z’n drietjes vorm gaf, waarop
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ik mijn werk een nieuwe impuls heb gegeven. Blij ben ik over het geluk dat 
we nu hebben met zijn zessen, ondanks het verdriet op de achtergrond. Blij 
ben ik over de wijze waarop familie en vrienden ons gesteund hebben en ons 
nieuw geluk gunnen. En tot slot de enorme blijdschap over de afronding van 
dit proefschrift nu!
Dankwoord
Allereerst wil ik alle patiënten bedanken, die hebben meegewerkt aan de 
onderzoeken en bereid waren extra tijd en extra controles te laten uitvoeren. 
Jullie namen en nemen een speciale plaats in.
Prof. dr. Th. Thien, beste Theo, ik mag je niet bedanken voor je inzet als 
promotor, want jij vindt dat een geheel vanzelfsprekende verantwoordelijkheid 
van de promotor. Waar ik je wel voor wil bedanken is de manier waarop je daar 
vorm aan hebt gegeven met name in de laatste jaren. Ik ben je dankbaar voor 
je coaching en ik ben trots de rij van vele promovendi af te sluiten.
Dr. M. den Heijer, beste Martin, bedankt voor de begeleiding in de afgelopen 
jaren als collega en mens. Wetenschap blijft inderdaad mensenwerk. Je was 
ook copromotor van Lieke. Een van je bijzondere eigenschappen die zonder 
p-waarde toch significant aanwezig is: jij weet als geen andere dokter statistiek 
en epidemiologie simpel en eenvoudig te laten lijken.
Dr. M. Janssen, beste Mirian, als duopartner tijdens de opleiding tot internist- 
vasculair geneeskunde en als copromotor hebben we veel samengewerkt en 
doen dat nu nog. Je was mijn steun en toeverlaat, die op een hele praktische 
en concrete manier zorgde voor de voortgang van de studies en het schrijven. 
Zoals je zelf in jouw proefschrift al stelde: de problematiek rondom veneuze 
trombose is bloedstollend. Nu dit recidief! Het resultaat van een gezamenlijke 
hobby en vriendschap.
Dr. H. Wollersheim, beste Hub, jij benaderde me om bij patiënten met 
trombosebenen de poliklinische behandeling te organiseren en onderzoek 
te gaan doen, met op een A4-tje allerlei onderzoeksvragen. Jaren later 
introduceerde je me in de wereld van kwaliteit en veiligheid en audits, werk 
dat ik nu met veel plezier doe. Dit proefschrift is het lange termijn gevolg van 
jouw initiatief destijds.
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Daarnaast wil ik alle andere medewerkers bedanken die betrokken waren bij de 
Post Trombose Studie en daarvoor extra werkzaamheden hebben verricht:
De (dienstdoende) AIOS en/of internisten en de verpleegkundigen van de 
spoedeisende hulp voor de inclusie van patiënten met verdenking DVT.
De medewerkers van het voormalig Centraal Hematologisch Laboratorium 
en de voormalige Afdeling Chemische Endocrinologie (beide nu afdeling 
Laboratoriumgeneeskunde) voor het verwerken en invriezen van de bloed­
monsters.
Gerard Pesman en Johanna van der Ven-Jongekrijg voor de coördinatie op 
het lab en de bepalingen.
De verpleegkundigen en assistenten van de poli voor het zwachtelen, 
informeren en begeleiden van de patiënten.
De medewerkers van het vaatfunctielaboratorium voor de flexibele planning 
en het uitvoeren van vaatfunctietesten, met name Suzanne Holewijn, Anita 
Theloosen en Ricky van Oorschot, bedankt!
De dermatologen voor de beoordeling van de benen: Carine van der Vleuten, 
Elke de Jong en Marieke Seyger, zonder jullie geen eindpunt in deze studie. 
Voor het waarnemen bij mijn afwezigheid de collega’s van de vasculaire 
geneeskunde: Pieter-Willem Kamphuisen, Ab Loualidi en Arjen Hoogendam. 
Voor het meewerken aan de studies in het kader van de wetenschappelijke 
stages: Janine van Rossum en Teun van den Hurk.
Collega’s uit het Canisius Wilhelmina Ziekenhuis, het Rijnstate en de INR 
Trombosedienst voor de onderlinge samenwerking.
Verder wil ik alle collega’s bedanken, allereerst van de afdeling Algemeen 
Interne Geneeskunde -  en speciaal van de sectie Vasculaire Geneeskunde -  
voor de samenwerking en de steun in de afgelopen jaren.
Prof. dr. J.W.M. Lenders, beste Jacques, bij het ALCO werd je mijn mentor en 
dat ben je gebleven.
Prof. dr. J.W.M. van der Meer, beste Jos, jij was getuige van mijn allereerste 
patiëntpresentatie als co-assistent in de grote visite: een patiënte met een 
trombosebeen, ik denk dat daar mijn voorliefde voor trombosebenen geboren is. 
Prof. dr. A.F.H. Stalenhoef, beste Anton, bedankt voor de ondersteuning als 
opleider en collega en je vertrouwen in mij binnen de sectie.
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Ook de collega’s bij het Instituut voor Waarborging van Kwaliteit en Veiligheid 
en het voormalige Bureau Kwaliteit wil ik bedanken voor de prettige werksfeer. 
We maken als auditteam een enorme ontwikkeling en professionalisering door 
maar verliezen het werkplezier daarbij niet uit het oog.
De dames van de buitenhoek, we hebben promotielief en leed gedeeld, maar 
vooral ook ‘echt lief en leed’ tijdens en na onze buitenhoekperiode. Daarmee 
zijn hechte vriendschappen ontstaan, die ook over de Nederlandse grenzen 
worden voortgezet.
Lieve vrienden, ‘oude vrienden’ van mij, van Marc, van ons, nieuwe vrienden, 
jullie steun was onmisbaar en niet te beschrijven. Door het delen van vreugde, 
maar ook van verdriet groeien vriendschappen. Het voordeel van de huidige 
situatie is dat we veel vrienden hebben, nadeel is dat tijd en aandacht verdeeld 
moeten worden, dank voor jullie begrip. Sodanogianen, het kerstdiner met 
twee extra glazen blijft bijzonder!
Lieve familie en schoonfamilies (drie!), ik vind het heel bijzonder hoe we als 
families verdriet en blijdschap delen en iedereen blij voor ons is met ons 
nieuwe geluk. Ik denk dat het niet vanzelfsprekend is, dat de banden zo goed 
zijn. De logeerweekenden en weken zijn een genot voor de kinderen, maar 
ook voor ons!
Mam, dank voor de manier waarop jullie mij gestimuleerd hebben, voor 
de gezelligheid en de steun na het overlijden van Marc. De maandag- 
jazzballetavonden in Arnhem, waarbij jullie oppasten, waren voor mij een 
heerlijke ontspanning. Ook toen pap plotseling overleed, bleef je dit doen. We 
hebben een onvergetelijke reis naar Nieuw-Zeeland gemaakt. Ik ben trots op 
de activiteiten die je onderneemt en je kracht.
Arjanne, via Marc heb ik je leren kennen en bij vele avondjes Triviant, een aantal 
gezamenlijke zeilvakanties en de nodige wandel- en borrelmiddagen zijn we 
hechte vriendinnen geworden; je had ook al de ‘eer’ als ceremoniemeester bij 
ons huwelijk.
Petra, als collega’s in de buitenhoek raakten we bevriend en dat is de afgelopen 
jaren verder uitgegroeid tot een vriendschap met een hoge mate van kwaliteit. 
‘Je kunt me altijd bellen’, bij jullie durfde ik dat ook echt te doen. Ik vind het fijn 
dat jullie me nu ook bij deze gelegenheid willen bijstaan als paranimfen.
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Lieve Nikki en Roos, Lieke zal altijd de allerliefste moeder zijn, maar ik ben 
dankbaar en gelukkig als puntjepuntjemoeder en met ons grote gezin.
Frank, na regen komt zonneschijn. Onze liefde is het beste wat ons is 
overkomen na het verlies van onze partners. Ik hoop dat we nog heel lang vele 
zonuren hebben samen.
Lieve Bram en Tim, mijn kleine grote mannen, ter nagedachtenis aan papa 
draag ik dit boekje aan jullie op. Ik zie zoveel van papa in jullie terug. Papa was 
altijd supertrots op jullie en zou dat nu zeker nog meer zijn. Ik wil hier alleen 
nog maar zeggen dat ook ik heel erg trots ben en heel veel van jullie hou!
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Edith Klappe werd geboren op 2 juli 1967 in 
Deventer. Ze volgde het gymnasium op het 
Geert Groote College te Deventer en behaalde 
in 1985 het diploma. Na uitloting voor de studie 
Geneeskunde volgde ze de propadeuse Fysio­
therapie aan de Academie voor Fysiotherapie 
te Deventer.
In 1986 startte ze de studie Geneeskunde in Nijmegen. Naast de studie was 
ze actief in diverse blokcommissies en als bestuurslid van de Medische 
Faculteits Vereniging. In 1993 werd het artsexamen behaald, waarna ze 
enkele maanden als arts-assistent Interne Geneeskunde werkte in het 
Elisabeth Gasthuis te Arnhem. In 1994 startte de opleiding tot internist in het 
Sint Joseph Ziekenhuis te Veldhoven (huidige Maxima Medisch Centrum) 
met als opleider Dr. P. Gerlag. In 1997 vervolgde ze de opleiding in het UMC 
St Radboud (opleider Prof. Dr. J.W.M. van der Meer) te Nijmegen, waarna in 
2000 de registratie tot internist volgde.
Het opzetten van de poliklinische behandeling van patiënten met trombose- 
benen leidde tot het opzetten van het onderzoek dat nu geresulteerd heeft in 
dit proefschrift. Van 2003 tot en met 2005 volgde ze de opleiding tot internist- 
vasculair geneeskundige. Nu is ze als zodanig werkzaam in het UMC St 
Radboud bij de afdeling Algemeen Interne Geneeskunde, sectie Vasculaire 
Geneeskunde.
Naast de patiëntenzorg is het toetsen en verbeteren van de kwaliteit en 
veiligheid ziekenhuisbreed de focus in haar huidige werkzaamheden. Sinds 
2007 is ze werkzaam als intern auditor bij Bureau Kwaliteit. In 2009 is de 
Unit interne audit ondergebracht in het Instituut voor Waarborging van Kwaliteit 
en Veiligheid.
Sinds 26 september 2005 is ze weduwe van Marc Roumen, met wie ze in 1996 
was getrouwd en met wie ze twee zonen kreeg, Bram en Tim. Samen vormen 
ze sinds 2009 een gezin met Frank Hoogesteger en Nikki en Roos.
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